

#### INTRODUCTION

- Antipsychotic medications have been used for over 50 years to treat schizophrenia and a variety of other psychiatric disorders (*Miyamoto et al 2005*).
- Antipsychotic medications generally exert their effect in part by blocking dopamine (D)-2 receptors (*Crismon et al 2020*).
- Antipsychotics are divided into 2 distinct classes based on their affinity for D2 and other neuroreceptors: typical antipsychotics, also called first-generation antipsychotics (FGAs), and atypical antipsychotics, also called second-generation antipsychotics (SGAs) (*Miyamoto et al 2005*).
- Atypical antipsychotics do not have a uniform pharmacology or mechanism of action; these differences likely account for the different safety and tolerability profiles of these agents (*Crismon et al 2020, Jibson et al 2021*). The atypical antipsychotics differ from the early antipsychotics in that they have affinity for the serotonin 5-HT<sub>2</sub> receptor in addition to D<sub>2</sub>.
  - Clozapine is an antagonist at all dopamine receptors (D<sub>1-5</sub>), with lower affinity for D<sub>1</sub> and D<sub>2</sub> receptors and high affinity for D<sub>4</sub> receptors. Aripiprazole and brexpiprazole act as partial agonists at the D<sub>2</sub> receptor, functioning as an agonist when synaptic dopamine levels are low and as an antagonist when they are high. Cariprazine is a partial agonist at D<sub>2</sub> and D<sub>3</sub>. Pimavanserin does not have dopamine blocking activity and is primarily an inverse agonist at 5-HT<sub>2A</sub> receptors. The remaining atypical antipsychotics share the similarity of D<sub>2</sub> and 5-HT<sub>2A</sub> antagonism, but differ in activity at other central nervous system (CNS) receptor classes.
- There are a number of atypical antipsychotic formulations available as both branded and generic products. Food and Drug Administration (FDA)-approved indications for the atypical antipsychotics include irritability associated with autistic disorder, bipolar disorder, Tourette's disorder, major depressive disorder (MDD), schizophrenia, schizoaffective disorder, and hallucinations and delusions associated with Parkinson's disease (PD) psychosis.
- Autism
  - Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by impairment in socialization, communication, and behavior (*Weissman et al 2019*).
  - ASD are more common in males than females and estimates of prevalence vary based on populations studied.
  - Data from the Autism and Developmental Disabilities Monitoring Network in the U.S. reported a prevalence of 18.5 per 1000 children at age 8 in 2016 (*Centers for Disease Control [CDC] 2021*).
  - The pathogenesis of ASD is not completely understood but is believed to have a genetic component, which alters brain development (*Augustyn 2020*).
  - Overall treatment goals include maximization of functioning, improvement in quality of life, and helping the patient achieve and maintain independence.
  - Specific treatment goals include improving social, communication, and adaptation skills, improving academic functioning, and decreasing nonfunctional behaviors.
  - Treatments include educational and behavioral therapies and pharmacologic interventions to treat targeted symptoms including aggression, impulsivity, hyperactivity, anxiety, sleep disturbances, and depression (*Weissman et al 2019*).
- Bipolar disorder
  - Bipolar disorder is characterized by discrete mood instability. The lifetime prevalence of bipolar disorder is reported to be between 1% and 3%, although the true prevalence is uncertain (*Stovall 2020*).
  - Genetics, in addition to environmental factors, appear to play an important role in the pathogenesis of bipolar disorder.
  - Drugs commonly used to treat acute mania or hypomanias include lithium, anticonvulsants, and antipsychotics. Benzodiazepines may be helpful when adjunctive treatment is needed for insomnia, agitation, or anxiety (*Stovall 2021*).
- Major depressive disorder (MDD)
  - MDD manifests with symptoms of depressed mood, loss of interest or pleasure in almost all activities, altered sleep, change in appetite or weight, poor energy and/or concentration, thoughts of worthlessness, and potentially thoughts of death or suicide (*Teter et al 2021*).

- For the diagnosis of MDD, patients must have  $\geq 5$  symptoms that have been present during the same 2-week period or represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. The goal of treatment is full remission (*Diagnostic and Statistical Manual of Mental Disorders [DSM] V 2013*).
- Based on data from 2013 to 2016, approximately 8.1% of individuals aged  $\geq 20$  years in the United States (U.S.) meet the criteria for depression. Women are more likely to experience symptoms of depression in their lifetime as compared to men (10.4% vs 5.5%) ([CDC 2021](#)).
- Schizophrenia
  - Schizophrenia is a disorder involving chronic or recurrent psychosis and is associated with significant functional impairment. Schizophrenia is believed to be caused by an increase in the cerebral activity of dopamine in the mesolimbic and/or mesocortical regions of the brain ([Keepers et al 2021](#)).
  - The disease includes positive symptoms such as hallucinations, delusions, and disorganized speech, as well as negative symptoms including flat affect, cognitive impairment, and impairment in executive functioning (*DSM V 2013*, [Keepers et al 2021](#)).
  - For the diagnosis of schizophrenia, patients must have  $\geq 2$  symptoms that have been present for a significant portion of time during a 1-month period and continuous signs of the disturbance persist for at least 6 months. Symptoms must include 1 of the following: delusions, hallucinations, and disorganized speech, but may also include grossly disorganized or catatonic behavior, and negative symptoms (*DSM V 2013*).
  - The prevalence of schizophrenia is approximately 0.25% to 0.64%, and the lifetime incidence is 10.2 to 22 per 100,000 person-years (*McGrath et al 2008, National Institute of Mental Health, van Os et al 2009*).
  - The pathogenesis of schizophrenia is unknown, and may be related to disruption(s) in one or more neurotransmitter systems ([Fischer and Buchanan 2020\[b\]](#)).
  - Symptoms of schizophrenia fall into 3 categories: positive symptoms (eg, hallucinations, delusions, disorganized thoughts and behavior), negative symptoms (eg, flat affect, decreased expressiveness, apathy), and cognitive symptoms (eg, impaired attention, memory, and executive functioning) ([Fischer and Buchanan 2020\[a\]](#)).
- Tourette's disorder
  - Tourette's disorder ranges greatly in terms of symptom severity and is often associated with comorbidities ([Murphy et al 2013](#)).
  - Tourette's disorder is characterized by persistent and repetitive motor and/or vocal tics, and onset is typically observed in childhood. For diagnosis, tics need to be present for at least 1 year. The pathophysiology of chronic tic disorders is not known but believed to be due to motor issues at both cortical and subcortical levels that are not properly modulated at the cortico-striatal-thalamo-cortical circuits.
  - Other comorbidities often observed with Tourette's disorder include attention-deficit hyperactivity disorder (ADHD) and obsessive compulsive disorder (OCD).
  - The prevalence of chronic tic disorders has been estimated as 0.5% to 3%, with approximately 7% of school-age children having had tics in the previous year.
- Parkinson's disease psychosis
  - Parkinson's disease is characterized by motor symptoms, which include tremor, bradykinesia, rigidity, and postural instability ([Bozymski et al 2017](#)).
  - Nonmotor symptoms can also occur in PD, which include autonomic dysfunction, sensory disturbances, and neuropsychiatric manifestations such as hallucinations, delusions, cognitive impairment, sleep disturbances, depression, and anxiety.
  - Approximately 60% of patients with PD develop psychosis.
  - For the diagnosis of PD psychosis, patients must meet the following criteria: primary diagnosis of PD; present with at least delusions, hallucinations, illusions, or false sense of presence; symptoms recurrent or continuous for at least 1 month; and exclusion of dementia-related psychosis or psychotic disorders.
- The agents included in this review are listed in Table 1 by brand name. Those drugs excluded from this review include Equetro (carbamazepine ER) capsule. Since there are multiple branded agents that contain the same generic component, the remaining tables in the review are organized by generic name. This review is restricted to the atypical antipsychotic agents and their respective FDA-approved indications.
  - Aripiprazole lauroxil is the prodrug of aripiprazole, and paliperidone is the active metabolite of risperidone.
- Medispan class: Antipsychotics/Antimanic agents; Antipsychotics – Misc., Quinolinone derivatives, Dibenzo-oxepino Pyrroles, Dibenzodiazepines.

**Table 1. Medications included within class review**

Drug	Generic
<b>Single Entity Agents</b>	
Abilify (aripiprazole tablets)	✓
aripiprazole orally disintegrating tablets (ODT), oral solution	✓ *
Abilify MyCite (aripiprazole tablet with sensor)	-†
Caplyta (lumateperone capsules)	-
Clozaril (clozapine tablets)	✓
Fanapt (iloperidone tablets)	-
clozapine ODT	✓ *
Geodon (ziprasidone hydrochloride [HCl] capsules)	✓
Geodon (ziprasidone mesylate injection)	✓
Invega (paliperidone extended-release [ER] tablets)	✓
Latuda (lurasidone tablets)	-
Nuplazid (pimavanserin tablets, capsules)	-
Rexulti (brexpiprazole tablets)	-
Risperdal (risperidone tablets, oral solution)	✓
risperidone ODT	✓ *
Saphris (asenapine sublingual tablet)	✓
Secuado (asenapine transdermal system)	-
Seroquel (quetiapine tablets)	✓
Seroquel XR (quetiapine ER tablets)	✓
Versacloz (clozapine oral suspension)	-
Vraylar (cariprazine capsules)	-
Zyprexa (olanzapine tablets, injection)	✓
Zyprexa Zydys (olanzapine ODT)	✓
<b>Long-Acting Injectable Products</b>	
Abilify Maintena (aripiprazole ER)	-
Aristada (aripiprazole lauroxil ER)	-
Aristada Initio (aripiprazole lauroxil ER)	-
Invega Sustenna (paliperidone palmitate)	-
Invega Trinza (paliperidone palmitate)	-
Perseris (risperidone ER)	-
Risperdal Consta (risperidone microspheres)	-
Zyprexa Relprevv (olanzapine pamoate)	-
<b>Combination Products</b>	
Symbyax (olanzapine/fluoxetine capsules)	✓

\* Brand product discontinued; generic products are available.

† Abilify MyCite is the only drug-device combination product, comprised of a tablet with an embedded sensor, a wearable sensor patch, a smartphone application, and a web-based portal.

(Drugs@FDA 2021, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2021)

## INDICATIONS

- The following summarizes all FDA-approved indications:

- Autism: Aripiprazole and risperidone are the only agents indicated for the treatment of irritability associated with autistic disorder in pediatric patients (aged 6 to 17 years and 5 to 17 years, respectively).
- Bipolar disorder: All oral agents in this class review are indicated for use in bipolar disorder, except clozapine, iloperidone, **lumateperone**, paliperidone, brexpiprazole, and pimavanserin. Aripiprazole ER (Abilify Maintena only) and Risperdal Consta are the only long-acting injectables indicated for the treatment of bipolar disorder.
  - Oral aripiprazole, olanzapine/fluoxetine, risperidone, quetiapine, asenapine, and lurasidone are approved for use in pediatric patients  $\geq 10$  years of age with bipolar disorder. Oral olanzapine is approved for use in patients  $\geq 13$  years of age with bipolar disorder.
- Depression: Aripiprazole, brexpiprazole, and quetiapine ER are indicated as adjunctive treatment for MDD in patients already taking an antidepressant. Olanzapine/fluoxetine is indicated for treatment-resistant depression.
- Schizophrenia: All agents in this class review are indicated for use in schizophrenia with the exception of pimavanserin, and the combination agent, Symbyax (olanzapine/fluoxetine). Clozapine and paliperidone products, excluding Invega Trinza, are indicated for the treatment of schizoaffective disorder. Clozapine is the only agent in this class that is FDA-approved for treatment-resistant schizophrenia.
  - Oral aripiprazole (with the exception of tablets with sensor), lurasidone, olanzapine, quetiapine, and risperidone are approved for use in patients  $\geq 13$  years of age and paliperidone oral products are approved for patients  $\geq 12$  years of age with schizophrenia.
- Tourette's Disorder: Aripiprazole is the only agent indicated for the treatment of Tourette's disorder in pediatric patients, aged 6 to 18 years.
- Parkinson's disease psychosis: Pimavanserin is the first atypical antipsychotic FDA-approved for use in patients with PD psychosis.
- Prescribing considerations: The labeling for iloperidone and ziprasidone state that when deciding among the alternative treatments, the prescriber should consider that these drugs are associated with prolongation of the QTc interval. In addition, patients must be titrated to an effective dose of iloperidone; thus control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to other antipsychotics that do not require similar titration.
- Table 2 highlights FDA-approved indications at a high level.



**Table 2. Food and Drug Administration approved indications**

Agent	Autism	Bipolar disorder: manic/mixed	Bipolar disorder: depressive	Depression – treatment-resistant	MDD: adjunct	Schizoaffective disorder	Schizophrenia	Schizophrenia: treatment-resistant	Tourette's Disorder	Parkinson's disease psychosis
<b>Single Entity Products</b>										
aripiprazole	✓ *	✓ *¶	-	-	✓ ¶	-	✓ *¶	-	✓ *	-
asenapine	-	✓ *§	-	-	-	-	✓	-	-	-
brexpiprazole	-	-	-	-	✓	-	✓	-	-	-
cariprazine	-	✓	-	-	-	-	✓	-	-	-
clozapine	-	-	-	-	-	✓	-	✓	-	-
iloperidone	-	-	-	-	-	-	✓	-	-	-
lumateperone	-	-	-	-	-	-	✓	-	-	-
lurasidone	-	-	✓ *	-	-	-	✓ *	-	-	-
olanzapine	-	✓ *	-	-	-	-	✓ *	-	-	-
paliperidone	-	-	-	-	-	✓	✓ *	-	-	-
pimavanserin	-	-	-	-	-	-	-	-	-	✓
quetiapine	-	✓ *	✓	-	✓ †	-	✓ *	-	-	-
risperidone	✓ *	✓ *	-	-	-	-	✓ *	-	-	-
ziprasidone HCl	-	✓	-	-	-	-	✓	-	-	-
ziprasidone mesylate	-	-	-	-	-	-	✓ §	-	-	-
<b>Long-Acting Injectable Products</b>										
aripiprazole ER (Abilify Maintena)	-	✓	-	-	-	-	✓	-	-	-
aripiprazole lauroxil ER (Aristada, Aristada Initio)	-	-	-	-	-	-	✓	-	-	-
paliperidone palmitate (Invega Sustenna)	-	-	-	-	-	✓	✓	-	-	-
paliperidone palmitate (Invega Trinza)	-	-	-	-	-	-	✓	-	-	-
risperidone microspheres	-	✓	-	-	-	-	✓	-	-	-

Agent	Autism	Bipolar disorder: manic/mixed	Bipolar disorder: depressive	Depression – treatment-resistant	MDD: adjunct	Schizoaffective disorder	Schizophrenia	Schizophrenia: treatment-resistant	Tourette's Disorder	Parkinson's disease psychosis
(Risperdal Consta)										
risperidone ER (Perseris)	-	-	-	-	-	-	✓	-	-	-
olanzapine pamoate ER (Zyprexa Relprevv)	-	-	-	-	-	-	✓ ‡	-	-	-
<b>Combination Products</b>										
olanzapine/fluoxetine	-	-	✓ *	✓	-	-	-	-	-	-

Abbreviations: ER = extended release, IM = intramuscular, ODT = orally disintegrating tablet

\*FDA-approved indications for pediatric patients.

† Indicated for the ER formulation.

‡ Patients must be observed by a health care professional for 3 hours post-dose administration with Zyprexa Relprevv.

§ IM injection indicated for acute agitation associated with schizophrenia.

|| IM injection indicated for acute agitation associated with schizophrenia and bipolar mania.

¶ Indicated for the drug-device combination with tablet and sensor. The ability to improve patient compliance or modify aripiprazole dosage has not been established. The ability to track drug ingestion in “real-time” or during an emergency is not recommended because detection may be delayed or not occur.

¥ Saphris sublingual tablets indicated for bipolar disorder, but not Secuado patches.

(Prescribing information: Abilify 2020, Abilify Maintena 2020, Abilify MyCite 2020, Aristada 2021, Aristada Initio 2021, Caplyta 2019, Clozaril 2021, Fanapt 2017, Geodon 2020, Invega 2021, Invega Sustenna 2021, Invega Trinza 2021, Latuda 2019, Nuplazid 2020, Perseris 2019, Rexulti 2020, Risperdal 2021, Risperdal Consta 2021, Saphris 2017, Secuado 2019, Seroquel 2020, Seroquel XR 2020, Symbyax 2021, Versacloz 2020, Vraylar 2019, Zyprexa 2020, Zyprexa Relprevv 2020, Zyprexa Zydys 2020)

- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

## CLINICAL EFFICACY SUMMARY

- The goal of this review is to evaluate key published literature regarding atypical antipsychotics for FDA-approved indications in children, adolescents, and adults. Numerous studies evaluating the efficacy of antipsychotic medications have been conducted. In clinical practice, the role of the atypical antipsychotics has been clearly established for the treatment of bipolar disorder and schizophrenia. In general, clinical consensus guidelines do not differentiate one agent from another, supporting the concept that all patients will require an individualized approach to treatment selection, taking into account the agent's safety profile and patient's individual risk factors.
- Key clinical studies evaluating the roles of atypical antipsychotic agents in the treatment of FDA-approved indications are included in the review. However, in recognition of the vast number of published studies of older atypical antipsychotics in adults, only a selection of randomized controlled studies (RCTs), systematic reviews (SRs), and meta-analyses (MAs) are presented.

## CHILDREN/ADOLESCENTS

- The Agency for Healthcare Research and Quality (AHRQ) conducted a SR evaluating the safety and efficacy of antipsychotics in children and adolescents. The review included 135 studies of atypical antipsychotics (aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone), conducted in patients 24 years of age or younger, and used for various psychiatric conditions including schizophrenia and related disorders, autism spectrum disorders, bipolar disorder, and tic disorder, among others. Overall, indications associated with moderate strength evidence for the use of atypical antipsychotics included schizophrenia and related psychoses, bipolar disorder, autism spectrum disorders, and ADHD. The risk of weight gain was highest for olanzapine, clozapine, and lurasidone. It was found that atypical antipsychotics probably increase short-term risk for high triglyceride levels, extrapyramidal symptoms, sedation, and somnolence vs placebo (*Pillay et al 2017*).

### Autism Spectrum Disorder

- For the treatment of irritability associated with autistic disorder, risperidone has been approved in pediatric patients aged 5 to 17 years and aripiprazole has been approved in patients aged 6 to 17 years. Very few RCTs have been conducted evaluating safety and efficacy, and only 1 low-quality study has been conducted evaluating comparative effectiveness. The primary outcome measure in trials was the change from baseline to endpoint in the Aberrant Behavior Checklist-Irritability subscale of the ABC (ABC-I), which measured symptoms of irritability in autistic disorder. One risperidone trial measured the Clinical Global Impression-Change (CGI-C) scores as a co-primary outcome measure.
- The safety and efficacy of aripiprazole was evaluated in 2 placebo-controlled (PC), 8-week trials. Over 75% of these subjects were under 13 years of age. In one of these trials, children and adolescents with autistic disorder (N = 98) received daily doses of placebo or aripiprazole 2 to 15 mg/day. The mean daily dose of aripiprazole at the end of the 8-week period was 8.6 mg/day. Aripiprazole significantly improved ABC-I subscale scores, including emotional and behavioral symptoms of irritability, aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods (*Owen et al 2009*). In the second of these trials in children and adolescents with autistic disorder (N = 218), 3 fixed doses of aripiprazole (5, 10, or 15 mg/day) were compared to placebo. ABC-I subscale scores were significantly decreased by 12.4 points with 5 mg/day, 13.2 with 10 mg/day, and 14.4 with 15 mg/day compared with 8.4 with placebo. Clinical Global Impressions (CGI)-Improvement scores were significantly improved: 2.6 points with 5 mg/day, 2.5 with 10 mg/day, and 2.5 with 15 mg/day compared with 3.3 with placebo. At the higher doses, ABC stereotypy, hyperactivity, CGI-S (Severity of Illness) scores, and other secondary measures were also improved (*Marcus et al 2009*).
- In one MA of 3 trials evaluating pediatric patients (N = 316) treated with aripiprazole, results demonstrated a greater increase in weight vs placebo (weight gain, 1.13 kg; 95% confidence interval [CI], 0.71 to 1.54; p < 0.00001), and a higher relative risk (RR) for sedation (RR, 4.28; 95% CI, 1.58 to 11.6; p = 0.004) and tremor (RR, 10.26; 95% CI, 1.37 to 76.63; p = 0.02) (*Hirsch et al 2016*).
- A 2018 MA evaluated the efficacy of aripiprazole in patients with autism spectrum disorder (N = 408) and found aripiprazole significantly improved irritability, hyperactivity, and inappropriate speech but not social withdrawal compared with placebo. The RR for response rate was also improved with aripiprazole (RR, 2.08; 95% CI, 1.24 to 3.46) (*Maneeton et al 2018*).

- The safety and efficacy of risperidone was evaluated in two 8-week and one 6-week, PC pivotal trials (McCracken et al 2002, Shea et al 2004). Approximately 90% of these subjects were under 12 years of age. In the two 8-week trials, the efficacy and safety of risperidone were measured in patients aged 5 to 16 years (N = 101) in weight-based, twice-daily doses of 0.5 to 3.5 mg/day (the RUPP trial) and in patients aged 5 to 12 years (N = 79) who received 0.02 to 0.06 mg/kg/day given once or twice daily (McCracken et al 2002, Shea et al 2004). The 6-week trial measured efficacy and safety in patients using lower than FDA-approved recommended dosing, and outcomes did not demonstrate efficacy (Risperdal prescribing information 2021). In the RUPP trial, risperidone-treated patients exhibited a 56.9% reduction in the mean ABC-I score from baseline, compared to a 14.1% reduction observed in the placebo group ( $p < 0.001$ ) (McCracken et al 2002). Risperidone was generally well tolerated, and most adverse events were mild and transient. Due to the uncertainty of a clear benefit with regard to the core symptoms of autism, the authors recommend that risperidone be reserved for the treatment of moderate-to-severe behavioral problems accompanying autism. In the second 8-week trial, risperidone patients demonstrated a 64% improvement in ABC-I subscale vs 31% improvement with placebo, which was a significant positive finding for hyperactivity (Shea et al 2004). Somnolence was the most frequently reported adverse event (72.5% vs 7.7%), and risperidone-treated subjects experienced statistically greater increases in weight (2.7 kg vs 1 kg), pulse rate, and systolic blood pressure.
- In an extension of the RUPP trial, 63 responders received open-label (OL) risperidone for another 16 weeks. Risperidone dose adjustments were allowed up to a maximum total daily dose of 3.5 mg/day. At the end of the 4-month extension, an intention-to-treat analysis revealed a minor, but clinically insignificant increase in ABC-I score. There was also a significant time effect on the ABC-I scale at the end of the 4-month extension phase ( $p = 0.02$ ) (McDougle et al 2005).
- Additional trials have been conducted measuring effects of risperidone; however, most trials included less than 50 patients. The outcomes of these trials are more sensitive to variability within the trials due to the small effect size (Aman et al 2008, Capone et al 2008, Gagliano et al 2004, Gencer et al 2008, Luby et al 2006, Miral et al 2008, Nagaraj et al 2006).
- One head-to-head, prospective, 8-week trial was conducted comparing the effects of aripiprazole  $\leq 10$  mg/day (mean dose, 5.5 mg/day) to risperidone  $\leq 3$  mg/day (mean dose, 1.12 mg/day) in patients (N = 59) aged 4 to 18 years of age. Approximately 65% of patients were diagnosed with autism, and additional diagnoses included Asperger syndrome, pervasive developmental disorder, and disruptive behavior disorder. Study authors stated double-blind (DB) techniques were not enforced for all patients. At the end of the trial, the mean change from baseline in ABC-I subscale score was not statistically different ( $p = 0.06$ ), but numerically favored risperidone. No differences were detected between groups for each adverse event or in the rate of discontinuations due to adverse events. Study authors concluded the safety and efficacy of both agents were comparable (Ghanizadeh et al 2014).
- A network MA evaluated 8 clinical trials (N = 878) with risperidone, aripiprazole, lurasidone, and placebo in pediatric autism spectrum disorder. Both risperidone and aripiprazole significantly reduced irritability compared with placebo with similar safety profiles. Lurasidone was not significantly different from placebo (Fallah et al 2019).

## Bipolar Disorder

### Manic/Mixed Episodes

- Aripiprazole, olanzapine, olanzapine/fluoxetine, risperidone, quetiapine and asenapine have FDA-approved indications for the treatment of pediatric patients diagnosed with bipolar disorder. All agents are approved for ages  $\geq 10$  years, except olanzapine which is approved in patients aged  $\geq 13$  years. In pediatric patients with bipolar disorder, evidence is extremely limited.
- In an AHRQ SR of 135 trials evaluating typical and atypical antipsychotics, a total of 19 trials measured efficacy and safety in adolescents with bipolar disorder. Compared with placebo, atypical antipsychotics decrease mania and depression symptoms slightly, and improve symptom severity and global functioning to a small extent. In addition, these agents probably increase response and remission rates vs placebo for manic/mixed phases (Pillay et al 2017).
- In a 21-day, DB, PC trial, 403 patients aged 10 to 17 years with bipolar I disorder were randomized to placebo or asenapine 2.5 mg, 5 mg, or 10 mg twice daily. The primary endpoint, change from baseline in Young Mania Rating Scale (YMRS) score, demonstrated a statistically significant and dose-dependent mean difference in YMRS scores at 21 days for all asenapine groups vs placebo (2.5 mg, -3.2;  $p = 0.0008$  vs 5 mg, -5.3;  $p < 0.001$  vs 10 mg, -6.2;  $p < 0.001$ ). Weight gain was higher across the asenapine groups, with 8% to 12% of patients experiencing  $\geq 7\%$  weight gain vs 1.1% of patients in the placebo group ( $p < 0.05$ ). Fasting glucose, insulin and cholesterol changes were also numerically higher in the asenapine groups vs placebo ( $p =$  not reported). Overall, asenapine was well tolerated and



showed efficacy in the treatment of this pediatric population, although the duration of the study period was brief (*Findling et al 2015*).

### Depressive Episodes

- Clinical trials measuring the safety and efficacy of atypical antipsychotics in depressive episodes in pediatric patients diagnosed with bipolar disorder are limited. Two trials examined efficacy of quetiapine in this population. In a small trial, a total of 32 patients aged 12 to 18 years were randomized to quetiapine 300 to 600 mg/day or placebo and followed over a period of 8 weeks. The primary endpoint was change in the Children's Depression Rating Scale, Revised Version (CDRS-R) score, in which both quetiapine and placebo groups exhibited statistically significant reductions in the CDRS-R scores from baseline ( $p < 0.001$ ), with no difference between groups (19 vs 20;  $p = 0.89$ ). All other efficacy measures were not statistically different from placebo (*DeBello et al 2009*). A similar 8-week trial enrolled 193 patients aged 10 to 17 years with acute bipolar depression. Patients were randomized to placebo or quetiapine XR 150 to 300 mg/day. The primary endpoint was change in CDRS-R score from baseline, with mean CDRS-R scores decreasing from baseline in both placebo (-29.6) and treatment (-27.3) groups. The difference between groups was not statistically significant (95% CI, -6.22 to 1.65;  $p = 0.25$ ). Triglyceride levels were elevated in 9.3% of the quetiapine XR group vs 1.4% of the placebo group. Mean weight gain was 1.3 kg in the quetiapine XR group vs 0.6 kg in the placebo group ( $p =$  not reported) (*Findling et al 2014*).
- In a DB, PC trial, 291 patients aged 10 to 17 years with bipolar I disorder, and depressive episodes were randomized 2:1 to olanzapine/fluoxetine or placebo for 8 weeks. Doses of olanzapine/fluoxetine were titrated to 12/50 mg daily over 2 weeks. The olanzapine/fluoxetine group had a 5-point greater mean decrease in CDRS-R score from baseline vs placebo (-28.4 vs -23.4;  $p = 0.003$ ). A total of 78.2% olanzapine/fluoxetine patients achieved response (defined as  $\geq 50\%$  reduction of CDRS-R score from baseline and a YMRS item 1 score  $\leq 2$ ) vs 59.2% of placebo group patients ( $p = 0.003$ ). Weight gain was more common in the olanzapine/fluoxetine group vs placebo (4.4 vs 0.5 kg;  $p < 0.001$ ), as well as increase in fasting total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (all  $p < 0.001$ ). Mean prolactin increase was higher in the olanzapine/fluoxetine group vs placebo ( $p < 0.001$ ) and increase in heart rate was also statistically significantly higher in the treatment group ( $p = 0.013$ ). This trial demonstrated efficacy in pediatric patients, but also demonstrated serious adverse effects (*Detke et al 2015*).
- In a DB, PC trial, 347 patients aged 10 to 17 years were assigned to flexible doses of lurasidone 20 to 80 mg/day or placebo. The primary endpoint was change from baseline to week 6 in the CDRS-R total score. At week 6 of therapy, treatment with lurasidone was associated with a significant improvement compared with placebo in CDRS-R total score (-21.0 versus -15.3;  $p < 0.0001$ ). Lurasidone also was associated with statistically significant improvements in the Clinical Global Impression-Bipolar Severity depression score (key secondary measure) and in measures of anxiety, quality of life, and global functioning (*DeBello et al 2017*).

### Schizophrenia and/or Schizoaffective Disorder

- In pediatric patients diagnosed with schizophrenia, FDA-approved treatments include aripiprazole, lurasidone, olanzapine, quetiapine and risperidone for use in patients  $\geq 13$  years of age and paliperidone oral products in patients aged  $\geq 12$  years. Many trials include a small sample size of patients, or are not well-designed. However, efficacy has been demonstrated and results are similar to adult trials.
- An SR and network MA of 12 RCTs ( $N = 2158$ ) evaluated 8 antipsychotics (aripiprazole, asenapine, paliperidone, risperidone, quetiapine, olanzapine, molindone, and ziprasidone) for treatment of children and adolescents with schizophrenia-spectrum disorders. Network MA found that change in Positive and Negative Syndrome Scale (PANSS) total, positive, and negative symptoms did not differ significantly between agents except for ziprasidone, which was inferior on PANSS total symptoms vs molindone, olanzapine, paliperidone, quetiapine, and risperidone, and inferior on PANSS negative symptoms vs molindone, olanzapine, and risperidone. All antipsychotics were superior to placebo on PANSS total symptom change except asenapine and ziprasidone. All antipsychotics, except ziprasidone, were superior to placebo on PANSS positive symptom change; additionally, all antipsychotics, except paliperidone, quetiapine, and ziprasidone, were superior to placebo on PANSS negative symptom change. Weight gain was primarily associated with olanzapine, while prolactin was increased with risperidone, paliperidone, and olanzapine (*Pagsberg et al 2017*).
- In an AHRQ SR of 135 trials evaluating typical and atypical antipsychotics, a total of 39 studies evaluated efficacy and safety in adolescents with schizophrenia. Compared with placebo, atypical antipsychotics as a class probably increase response rates; decrease slightly (not clinically significant for many patients) negative and positive symptoms; and

improve slightly global impressions of improvement, severity, and functioning. Six studies comparing risperidone vs olanzapine found little or no difference in their effects for negative and positive symptoms, response rates, and global impressions of severity (*Pillay et al 2017*).

- A Cochrane review compared atypical antipsychotic medications to placebo, typical antipsychotics, or another atypical antipsychotic in adolescents with psychosis. Compared to typical antipsychotics, there were no significant differences in Brief Psychiatric Rating Scale (BPRS) scores in an analysis of 5 trials with 236 patients. There was no evidence to suggest the superiority of atypical antipsychotics over typical antipsychotics; however, fewer adolescents dropped out due to adverse effects when administered an atypical antipsychotic (RR, 0.65; 95% CI, 0.36 to 1.15). Minimal evidence was available comparing one atypical antipsychotic to another. In terms of the number of patients who did not respond (defined as  $\leq 30\%$  reduction in BPRS score), results significantly favored clozapine, but increases in salivation, sweating, and glucose levels were observed vs olanzapine in 1 trial with 39 patients. Treatment with olanzapine, risperidone and clozapine was associated with weight gain. Aripiprazole was not associated with increased prolactin or dyslipidemia. Low-dose risperidone significantly decreased improvement in PANSS total score but also reduced the rate of extrapyramidal symptoms (EPS) vs standard-dose risperidone in 1 trial with 255 patients. Overall, efficacy between atypical and typical antipsychotics may be similar; however, safety benefits may favor treatment with atypical antipsychotics (*Kumar et al 2013*).
- A 6-week, randomized, PC trial evaluating the efficacy of lurasidone in acutely symptomatic adolescents with schizophrenia found that the least squares (LS) mean change in PANSS total score from baseline to week 6 was greater for the lurasidone 40 mg/day group (-18.6;  $p < 0.001$ ; effect size = 0.51) and the lurasidone 80 mg/day group (-18.3;  $p < 0.001$ ; effect size = 0.48) vs the placebo group (-10.5). The LS mean change from baseline to week 6 in CGI-S score was significantly greater for the lurasidone 40 mg/day group (-1.0;  $p < 0.001$ ; effect size = 0.49) and the lurasidone 80 mg/day group (-0.9;  $p = 0.0015$ ; effect size = 0.45) compared with the placebo group (-0.5). The most common adverse events in the lurasidone groups were nausea, anxiety, akathisia, somnolence, and vomiting (*Goldman et al 2017*).

#### Tourette's Disorder

- Aripiprazole is the only agent indicated for the treatment of Tourette's disorder. Efficacy and safety is based on low quality evidence in one fixed-dose and one flexible-dose trial. There is minimal evidence of safety and efficacy in this population.
- In one published, DB, PC, 10-week trial, aripiprazole significantly reduced total tic score (Yale Global Tic Severity Scale [YGTSS-TTS]; -15 vs -9.6) and phonic tic score (YGTSS-PTS; -7.4 vs -4.2), but not motor tic score, compared with placebo in patients aged 6 to 18 years with Tourette's disorder. The response rate (score of 1 or 2 on the Tourette's syndrome CGI-Improvement scale) was 66% vs 45%, respectively (*Yoo et al 2013*).
- In another similarly designed, unpublished, 8-week trial in patients aged 7 to 17 years who received weight-based aripiprazole, significant improvements compared with placebo were seen on YGTSS-TTS with a change of -13.4 and -16.9 points with low- and high-dose aripiprazole compared to -7.1 with placebo (*Abilify prescribing information 2020*).
- Aripiprazole was associated with increased body weight compared to placebo (range, 0.4 to 1.5 kg). Additional adverse reactions (incidence  $\geq 5\%$  and at least twice that for placebo) were sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, and increased appetite (*Abilify prescribing information 2020*). In one safety trial, aripiprazole had a safer cardiovascular profile vs pimozide, and was associated with a lower frequency of QT prolongation (*Gulisano et al 2011*).

#### **ADULTS**

- The AHRQ conducted an SR of literature on the safety and efficacy of antipsychotics in adults comparing typical and atypical antipsychotics. The review included studies of atypical antipsychotics (aripiprazole, asenapine, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone), conducted in patients 18 to 64 years of age, and used for the following FDA-approved indications: bipolar disorder, schizophrenia, and schizophrenia-related psychoses. The most frequent comparisons involved haloperidol, with 43 studies comparing haloperidol with risperidone and 37 studies comparing haloperidol with olanzapine. Nevertheless, the number of studies available for each comparison and outcome was often limited. Overall, indications associated with moderate to low strength evidence for the use of atypical antipsychotics included schizophrenia and schizophrenia-related psychoses. Bipolar disorder was associated with low strength of evidence. Few differences of clinical importance for outcomes of effectiveness were found. Patient-important outcomes were rarely assessed. Data were sparse for the 4 key adverse events deemed to be most

clinically important. In terms of efficacy, few differences were found between typical and atypical antipsychotic agents, specifically when compared to haloperidol and clinical significance (defined as  $\geq 20\%$  difference between interventions) was rarely found. The evidence regarding safety, particularly those adverse events of most interest (ie, diabetes, tardive dyskinesia, metabolic syndrome, and mortality) were insufficient to draw firm conclusions about the risks among treatment groups. No differences were found in mortality for chlorpromazine vs clozapine and haloperidol vs aripiprazole, or in metabolic syndrome for haloperidol vs olanzapine. The most frequently reported adverse events with significant differences were EPS; in most cases, the atypical antipsychotic had fewer EPS than haloperidol (*Abou-Setta et al 2012*).

## Bipolar Disorder

### *Manic/Mixed Episodes*

- All oral atypical antipsychotic agents in this class review are indicated for use in bipolar disorder, except clozapine, iloperidone, **lumateperone**, paliperidone, brexpiprazole, and pimavanserin. The following summarizes direct comparative evidence and recent MAs and SRs.
- A 2018 AHRQ SR of 156 trials concluded that symptoms of acute mania were modestly improved with asenapine, cariprazine, quetiapine, and olanzapine compared to placebo. Risperidone, ziprasidone, and paliperidone may also be effective for acute mania symptoms. Lithium was effective in the treatment of acute mania and prolonged the time to relapse compared to placebo, and this was the only agent that achieved a minimal clinically important difference in symptoms. All of these results were based on low-strength evidence because moderate and strong evidence was lacking (*Butler et al 2018*).
- In a 2012 AHRQ SR of 125 trials evaluating typical and atypical antipsychotics, a total of 12 measured efficacy and safety in adults with bipolar disorder. Compared to haloperidol, there was no difference in YMRS score for manic episodes for aripiprazole, olanzapine, and risperidone, and no difference in Montgomery-Asberg Depression Rating Scale (MADRS) score for aripiprazole in a total of 9 trials. In one trial of 350 patients, haloperidol was favored in terms of YMRS score over ziprasidone. Haloperidol produced lower relapse rates than aripiprazole in one trial with 347 patients and provided better response rates than ziprasidone in one trial of 350 patients. The most frequently reported adverse effects with significant differences were in the category of EPS and most often involved haloperidol. Haloperidol appears to be an equally effective treatment compared with the atypical antipsychotics; however, it is associated with more incidences of EPS compared to other agents (*Abou-Setta et al 2012*).
- A SR and MA of 15 RCTs and 1 observational study was conducted to evaluate the efficacy of maintenance treatment in bipolar disorder using atypical antipsychotics, either as monotherapy or as adjunctive therapy. As adjunctive therapy to lithium or valproate, MAs showed that treatment with aripiprazole (RR, 0.65; 95% CI, 0.50 to 0.85), quetiapine (RR, 0.38; 95% CI, 0.32 to 0.46), or ziprasidone (RR, 0.62; 95% CI, 0.40 to 0.96) reduced the overall risk of relapses in patients that had responded during the stabilization phase. Quetiapine was the only drug that reduced both manic and depressive episodes. Due to high risk of bias and low levels of evidence, no conclusions could be drawn for olanzapine or risperidone. For monotherapy, quetiapine was shown to be better than lithium/valproate for both manic and depressive relapses; no reliable conclusions could be made for olanzapine due to the low quality of evidence. Monotherapy with olanzapine, quetiapine, and risperidone were shown to be superior vs placebo in reducing the overall risk of relapse; no reliable conclusions could be made for aripiprazole due to the low quality of evidence (*Lindström et al 2017*).
- One SR of 9 RCTs (N = 1289) compared the effectiveness of atypical antipsychotics to placebo, either as monotherapy or as adjunctive treatment with a mood stabilizer. Atypical antipsychotics, either alone or in combination with mood stabilizers, had superior efficacy in treating manic symptoms of mixed episodes compared to placebo in short-term trials lasting 3 to 6 weeks ( $p < 0.00001$ ). Atypical antipsychotics also had superior efficacy in treating depressive symptoms of mixed episodes ( $p < 0.001$ ) (*Muralidharan et al 2013*).
- The efficacy and safety of asenapine in the treatment of manic or mixed bipolar I disorder were evaluated in 6 PC, and active-controlled (olanzapine) studies in adult patients, with or without psychotic features (*McIntyre et al 2009[a]*, *McIntyre et al 2010[a]*, *McIntyre et al 2009[b]*, *McIntyre et al 2010[b]*, *Szegedi et al 2011*, *Szegedi et al 2018*). In a pooled analysis of patients experiencing bipolar mania, asenapine and olanzapine were comparable in terms of reduction from baseline in YMRS scores at week 52 of therapy (*McIntyre et al 2010[b]*). A MA of various anti-manic therapy options found that asenapine was associated with a statistically significant improvement in YMRS scores from baseline compared to placebo (mean difference [MD], -0.3; 95% CI, -0.53 to -0.07), though it was less effective compared to olanzapine (0.22; 95% CI, 0.08 to 0.37) (*Cipriani et al 2011*). The most commonly reported adverse

events reported with asenapine included sedation, dizziness, somnolence and weight gain. Of note, it was calculated that for every 9 patients treated with olanzapine over asenapine, one would experience clinically significant weight gain with olanzapine (19% vs 31%) (*McIntyre et al 2009[b]*).

- The approval of cariprazine was based on the efficacy and safety from 3 flexible-dose, DB, PC, 3-week trials (*Calabrese et al 2015, Durgam et al 2015[a], Sachs et al 2015*). A total of 1047 adult patients with acute manic or mixed episodes were administered placebo or cariprazine 3 to 12 mg per day based on tolerability. Across trials, the mean daily dose was 8.8 mg per day and the mean final dose was 10.4 mg per day (*FDA/CBER summary review 2015*). All doses were superior to placebo in reducing YMRS and CGI-S scores and a significant reduction in YMRS was observed as early as 4 days in some studies and persisted until week 3. The proportion of YMRS remitters was significantly higher in the cariprazine group than placebo (difference range, 15 to 19%) (*Calabrese et al 2015, Durgam et al 2015[a], Sachs et al 2015*). Of note, doses higher than 6 mg had similar efficacy, but adverse events were less tolerable. Due to the long half-life and pharmacokinetics of the active metabolite, DDCAR, drug steady state was not achieved in trials (*FDA/CBER summary review 2015*). It is anticipated that late-onset of adverse reactions would be observed if assessed for a longer period. In bipolar studies, 4% of patients with normal hemoglobin A1c developed elevated levels ( $\geq 6.5\%$ ). According to a pooled analysis ( $n = 1940$  cariprazine-treated patients) within the FDA summary review, the most frequently observed adverse events include akathisia (14.2%), EPS (20.8%), constipation (7.6%), and nausea/vomiting (6 to 8%). The proportion of patients with weight increase  $\geq 7\%$  from baseline ranged from 1 to 3% across cariprazine doses.
- The efficacy and safety of risperidone 1 to 6 mg/day compared to olanzapine 5 to 20 mg/day were evaluated in a 3-week, DB, RCT in patients hospitalized for bipolar I disorder, manic or mixed episode, without psychotic features. Olanzapine and risperidone mean doses were 14.7 mg/day and 3.9 mg/day, respectively. There was no difference between groups in many outcome measures in remission or response in YMRS, 21-item Hamilton Rating Scale for Depression (HAM-D-21), or MADRS scales. More patients given olanzapine completed the trial compared with patients given risperidone (78.7% vs 67%, respectively). In total, 62.1% of patients in the olanzapine group and 59.5% of patients in the risperidone group were categorized as responders (defined as  $\geq 50\%$  reduction in the YMRS score at endpoint). Olanzapine-treated patients experienced significantly greater elevations in liver function enzymes and weight gain (2.5 kg vs 1.6 kg). Risperidone-treated patients experienced significantly more prolactin elevations and sexual dysfunction (*Perlis et al 2006[a]*).

### Depressive Episodes

- Placebo-controlled trials measuring effects for the treatment of bipolar depression have demonstrated efficacy with lurasidone, quetiapine (immediate- and extended-release [ER]), and olanzapine/fluoxetine as monotherapy and adjunctive treatment (*Calabrese et al 2005, Corya et al 2006, McElvoy et al 2010, Loebel et al 2014[a], Loebel et al 2014[b], Shelton et al 2005, Suppes et al 2010, Thase et al 2007, Young et al 2010*).
- Treatment with olanzapine/fluoxetine was superior to monotherapy with olanzapine and lamotrigine in achieving greater improvements in MADRS and CGI-BP (bipolar version) (*Tohen et al 2003, Brown et al 2009*). Patients treated with olanzapine/fluoxetine had significantly greater rates of treatment response and remission compared to those receiving olanzapine monotherapy (*Tohen et al 2003*). It is not clear if quetiapine outperforms lithium in terms of treatment of bipolar depression, as various studies have produced different results (*Chiesa et al 2012, Young et al 2010*).
- Meta-analyses have found that combination treatment with olanzapine/fluoxetine may be the optimal treatment for bipolar depression compared to other treatment options. However, the overall evidence quality was considered low, trials had limited durations, and a high placebo effect was observed. Olanzapine, quetiapine, lurasidone, valproate, selective-serotonin reuptake inhibitors (SSRIs), lithium, and tricyclic antidepressants (TCAs) also appeared to be effective, but with varied acceptability (*Fornaro et al 2016, Ostacher 2017, Silva et al 2013, Taylor et al 2014, Vieta et al 2010*). No notable efficacy differences were identified between atypical antipsychotics, suggesting that lurasidone, quetiapine, and olanzapine/fluoxetine may be reasonable choices.

### Major Depressive Disorder (MDD)

#### Key MDD Meta-Analyses

- A number of MAs and SRs have been conducted evaluating the safety and efficacy of atypical antipsychotics to augment treatment for MDD. Aripiprazole, brexpiprazole, and quetiapine ER are indicated for the treatment of MDD as

adjunctive treatment; and olanzapine, in combination with fluoxetine, is indicated for the treatment of treatment-resistant depression. The most recent, well-designed MAs have been summarized for efficacy and safety evaluations.

- One MA, which followed Cochrane methodologies, evaluated 17 trials of short-term duration ranging from 4 to 12 weeks. The analysis compared adjunctive atypical antipsychotics in combination with an SSRI/serotonin-norepinephrine reuptake inhibitor (SNRI) to SSRI or SNRI monotherapy in patients with refractory or treatment-resistant MDD. Results demonstrated that the augmentation of antidepressants with atypical antipsychotics (olanzapine, quetiapine, aripiprazole, and risperidone [Note: risperidone is not FDA-approved for this indication]) was more effective than antidepressant monotherapy in improving response and remission rates. However, adjunctive atypical antipsychotic therapy was associated with a higher discontinuation rate due to adverse effects (9.1% vs 2.6%). The attributable risk for the discontinuation rate due to adverse effects was 0.07 (number needed to harm [NNH], 16; 95% CI, 12 to 20) (*Wen et al 2014*).
- Another MA evaluated 14 trials in patients with current MDD and an inadequate response to at least 1 course of antidepressant medication treatment. Compared to placebo, the atypical antipsychotics significantly improved remission rates: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48 to 2.73), olanzapine/fluoxetine (OR, 1.42; 95% CI, 1.01 to 2), quetiapine (OR, 1.79; 95% CI, 1.33 to 2.42) and risperidone (OR, 2.37; 95% CI, 1.31 to 4.3). In terms of remission, all atypical antipsychotics were efficacious; however, olanzapine/fluoxetine had a higher number needed to treat (NNT) compared to other agents (NNT for olanzapine/fluoxetine, 19 vs NNT for aripiprazole, quetiapine, risperidone, 9). Treatment was associated with several adverse events, including akathisia (aripiprazole), sedation (quetiapine, olanzapine/fluoxetine and aripiprazole), abnormal metabolic laboratory results (quetiapine and olanzapine/fluoxetine), and weight gain (all 4 drugs, especially olanzapine/fluoxetine). However, little to no information was provided in detail regarding the adverse events (*Spielmann et al 2013*).

#### Adjunctive treatment for MDD

- Aripiprazole, brexpiprazole, and quetiapine ER are indicated for the treatment of MDD as adjunctive treatment. The following information describes the pivotal trials used for FDA-approval.
- The FDA-approval of aripiprazole for the adjunctive treatment of MDD was based on 2 PC, 6-week trials in adult patients (N = 381; N = 362) who had failed 1 to 3 courses of antidepressant therapy, including an inadequate response to 8 weeks of antidepressant treatment. Aripiprazole was superior to placebo in reducing the mean MADRS total scores and remission rates. The NNT to reduce remission rates (defined as MADRS total score  $\leq 10$  and  $\geq 50\%$  reduction in MADRS) was 10 (*Berman et al 2007, Marcus et al 2008*). Increased incidences of akathisia were seen across trials with one trial reporting a NNH of 4 (*Marcus et al 2008*). One pooled analysis of 3 similarly designed trials (N = 409) measured the effects of aripiprazole in older vs younger patients. Results demonstrated adjunctive aripiprazole was effective in improving depressive symptoms in older patients (50 to 67 years), and akathisia was the most commonly reported adverse event in both the older (17.1%) and younger (26%) patient groups (*Steffens et al 2011*). Other trials have demonstrated similar results (*Kamijima et al 2013, Papakostas et al 2005*). In a 12-week, randomized, DB, PC trial evaluating the safety and efficacy of aripiprazole for adjunctive MDD treatment in patients over the age of 60 years (N = 181), a higher percentage of patients achieved remission (defined as a MADRS score of  $\leq 10$ ) in the aripiprazole group as compared to placebo (44% vs 29%; p = 0.03; NNT 6.6). Similar to other studies, akathisia was the most common side effect in the aripiprazole group (26% vs 12%), and Parkinsonism was also more often reported (17% vs 2%) (*Lenze et al 2015*).
- The safety and efficacy of brexpiprazole was evaluated in 2 DB, PC, pivotal, 6-week trials in adult patients as an adjunct to antidepressant therapy for MDD. In the pivotal studies, brexpiprazole 2 mg daily doses significantly reduced the mean MADRS score, the primary endpoint, compared with placebo (Study 1 [N = 353], -8.4 points with brexpiprazole 2 mg vs -5.2 points with placebo) (*Thase et al 2015[a]*). In an FDA analysis, the brexpiprazole 1 mg and 3 mg dose did not reduce the mean MADRS score; however, an FDA analysis found evidence of efficacy based on phase 2 data, and per protocol and intention-to-treat analyses of Study 2 (*Thase et al 2015[b], FDA briefing document 2015*). The most common adverse reactions in MDD trials were akathisia (NNH, 15), increased weight (NNH, 20) and somnolence (NNH, 22); and in schizophrenia trials were increased weight (NNH, 48) and tremor (NNH, 51) (*Correll et al 2015, Kane et al 2015[a], Thase et al 2015[b]*). An SR and MA of 4 DB, randomized, PC trials evaluating the efficacy and safety of brexpiprazole for adjunctive treatment of MDD found that it was superior to placebo for MADRS (MD, -1.76; 95% CI, -2.45 to -1.07; p < 0.00001) and the HAM-D-17 (MD, -1.21; 95% CI, -1.71 to -0.72; p < 0.00001). The RRs for response and remission were 1.57 (95% CI, 1.29 to 1.91) and 1.55 (95% CI, 1.22 to 1.96), respectively (*Yoon et al 2017*).

- The FDA-approval of quetiapine fumarate ER as an adjunct to antidepressant therapy for the treatment of MDD was based on two 6-week, PC, fixed dose trials (N = 939) in doses of 150 mg or 300 mg/day. A pooled analysis of the 2 RCTs demonstrated that quetiapine fumarate 300 mg/day (58.3%;  $p < 0.01$ ; NNT, 9) significantly improved the MADRS response (defined as  $\geq 50\%$  decrease in MADRS total score), but quetiapine fumarate 150 mg/day (53.7%;  $p = 0.06$ ) did not compared to placebo (46.2%). However, MADRS remission was significantly improved for both the quetiapine fumarate 300 mg/day (36.5%;  $p < 0.001$ ; NNT, 8) and 150 mg/day doses (35.6%;  $p < 0.01$ ; NNT, 9) vs placebo (24.1%). The most common adverse events leading to discontinuation were somnolence and sedation. For the quetiapine fumarate 300 mg/day, 150 mg/day, and placebo groups, the mean weight gain was 1.3, 0.9, and 0.2 kg, and the incidence of EPS was 6.4, 3.8, and 4.2%, respectively (*Bauer et al 2010*).

#### *Treatment-resistant depression*

- Olanzapine, combined with fluoxetine, is the only agent in this class review that is indicated for treatment-resistant depression. Approval of olanzapine/fluoxetine for the acute treatment of treatment-resistant depression was based on 3 clinical trials of 8- (2 trials) and 12-week duration. Treatment with olanzapine/fluoxetine was generally more effective than monotherapy with either olanzapine or fluoxetine in improving MADRS scores; however, results in trials have been mixed (*Corya et al 2006, Shelton et al 2005, Thase et al 2007*). In one 12-week, DB trial, olanzapine/fluoxetine was compared to olanzapine, fluoxetine, or venlafaxine monotherapy. Olanzapine/fluoxetine demonstrated a statistical MADRS advantage over all monotherapy agents after week 1 which was maintained up to week 6; however, this effect was only sustainable over olanzapine monotherapy at week 12 (*Corya et al 2006*). Other trial data demonstrated that olanzapine/fluoxetine was not significantly different compared to other antidepressants such as nortriptyline and fluoxetine monotherapy in improving MADRS scores (*Corya et al 2006, Shelton et al 2005*).
- Treatment with olanzapine/fluoxetine has consistently demonstrated increases in the incidence ( $\geq 10\%$ ) of weight gain, increased appetite, somnolence, and dry mouth. Additional adverse events have varied in trials. Compared to fluoxetine and olanzapine monotherapy, the most common adverse events for olanzapine/fluoxetine (incidence  $\geq 10\%$ ) included peripheral edema and hypersomnia, which were significantly higher than that of fluoxetine monotherapy ( $p < 0.001$ ) (*Thase et al 2007*). Compared to olanzapine, fluoxetine or venlafaxine monotherapy, the most common adverse events for olanzapine/fluoxetine (incidence  $\geq 10\%$ ) included dizziness, asthenia, peripheral edema, and headache. More patients in the combination therapy group discontinued due to weight gain (*Corya et al 2006*). Compared to fluoxetine, olanzapine, and nortriptyline monotherapy, the most common adverse events for olanzapine/fluoxetine combination therapy (incidence  $\geq 10\%$ ) were asthenia, headache, anxiety, tremor, nervousness, insomnia, and nausea (*Shelton et al 2005*).

#### Schizophrenia and/or Schizoaffective Disorder

- All oral atypical antipsychotic agents in this class review are indicated for use in schizophrenia with the exception of the combination agent olanzapine/fluoxetine. Clozapine is the only agent indicated for treatment-resistant schizophrenia. Clozapine and paliperidone products, excluding Invega Trinza, are indicated for the treatment of schizoaffective disorder. The following is a summary of recent MAs and SRs, landmark trials in schizophrenia, and study evidence related to newer atypical antipsychotic agents (ie, asenapine, brexpiprazole, cariprazine, iloperidone, and lurasidone) that do not have extensive trial evidence.
- Based on a 2012 AHRQ SR of 125 trials evaluating typical and atypical antipsychotics, a total of 113 measured efficacy and safety in adults with schizophrenia or schizophrenia-related psychoses. Compared to haloperidol, there was no difference in PANSS (and/or Scale for the Assessment of Positive Symptoms [SAPS]) score for positive symptoms for aripiprazole, clozapine, olanzapine, quetiapine, and risperidone. Outcomes measuring negative symptoms demonstrated a significant difference in PANSS scores favoring aripiprazole for 1701 patients in 3 trials, risperidone for 4043 patients in 20 trials, and olanzapine-treatment for 3742 patients in 14 trials. When compared with haloperidol, risperidone yielded lower relapse rates for 1405 patients in 6 trials and olanzapine provided better response rates for 4099 patients in 14 trials and remission rates for 582 patients in 3 trials. The most common adverse effects with significant differences were in the category of EPS and most often involved haloperidol. Haloperidol appears to be equally effective to treatment with the atypical antipsychotics in terms of positive symptoms; however, for negative symptom scores aripiprazole, risperidone, and olanzapine may be better options for treatment. Olanzapine and risperidone may be better options when remission/relapse rates are considered (*Abou-Setta et al 2012*).

- One large Bayesian MA of 212 RCTs compared 15 antipsychotic medications for efficacy and safety outcomes in patients with schizophrenia or related disorders in short-term trials. The primary endpoint was efficacy measured by mean overall change in symptoms after 6 weeks and all antipsychotics were significantly more effective than placebo. Clozapine had the greatest mean difference in the change in symptom scores and was significantly superior to all other antipsychotics, including olanzapine and risperidone which have demonstrated some efficacy in treatment-resistant patients. After clozapine, olanzapine, and risperidone were significantly more effective than the other antipsychotics apart from paliperidone. Overall, effect sizes were small and there were some inconsistencies between results, but the authors did not consider that this was substantial enough to change the results. Safety assessment for the FDA-approved agents indicated that EPS was lowest for clozapine and highest for haloperidol; sedation was lowest for risperidone and highest for clozapine; weight gain was lowest for haloperidol and highest for olanzapine; prolactin increase was lowest for aripiprazole and highest for paliperidone; and QT prolongation was lowest for lurasidone and highest for ziprasidone. The authors concluded that the properties of antipsychotic drugs differed greatly among agents and that treatment should be fit to individual patients' needs. As the MA had many limitations, including substantial differences between studies, and uncertainties surround indirect comparisons, generalizability of the findings and authors' conclusions are limited. This is similar to many large atypical antipsychotic MAs (*Leucht et al 2013*).
- One Cochrane SR evaluated aripiprazole vs other atypical antipsychotics for the treatment of schizophrenia. Differences in efficacy between aripiprazole and other atypical antipsychotics (olanzapine, risperidone, and ziprasidone) demonstrated no advantage in terms of overall global state (defined as MD in CGI-S score) or mental state (defined as MD total change in PANSS score). When compared with any one of several new generation antipsychotic drugs in one RCT (N = 523), the aripiprazole group showed improvement in energy, mood, negative symptoms, somnolence, and weight gain. More nausea was seen in patients given aripiprazole (N = 2881; RR, 3.13; 95% CI, 2.12 to 4.61). Weight gain with aripiprazole-treatment was less common (N = 330; RR, 0.35; 95% CI, 0.19 to 0.64). Attrition ranged from 30% to 40% (no differences between groups). Due to the high attrition rates validity is limited, thereby making it difficult to make strong conclusions. There are limited data on the safety and efficacy of aripiprazole. Based on current available evidence, efficacy of aripiprazole appears to be similar and there may be benefits in terms of weight gain, but there appears to be an increased incidence of nausea compared to other agents (*Khanna et al 2014*).
- One Cochrane SR evaluated quetiapine compared to other atypical antipsychotics for the treatment of schizophrenia. Efficacy and safety were evaluated in 5971 patients across 35 RCTs. For the primary efficacy endpoint, PANSS total score, the comparator drugs may be more effective than quetiapine, but the clinical meaning of these data is unclear. There were no significant differences in efficacy between quetiapine and clozapine, but quetiapine was associated with fewer adverse events. Quetiapine demonstrated fewer movement disorders compared to risperidone (RR, 0.5; 95% CI, 0.36 to 0.69), olanzapine (RR, 0.51; 95% CI, 0.32 to 0.81), and paliperidone (RR, 0.64; 95% CI, 0.45 to 0.91). There are limited studies; however, data provide evidence that quetiapine-treated patients may need to be hospitalized more frequently than those taking risperidone or olanzapine. Quetiapine may be slightly less effective than risperidone and olanzapine in reducing symptoms, and it may cause less weight gain and fewer side effects and associated problems (such as heart problems and diabetes) than olanzapine and paliperidone, but more than risperidone and ziprasidone (*Asmal et al 2013*).
- The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a large, multi-center study initiated by the National Institute of Mental Health to examine the effectiveness of SGAs compared to FGAs in patients with chronic schizophrenia. It was intended to include patients treated in typical clinical settings and to reflect typical clinical practice in which individuals with schizophrenia may require multiple medication trials before finding one that is adequately both efficacious and tolerable. The study design allowed for patients who discontinued one study antipsychotic drug to enter subsequent phases of the study to receive additional antipsychotic medications (*Lieberman et al 2005, Stroupe et al 2006, Stroupe et al 2009*). Among the unexpected outcomes was the finding that, with the exception of clozapine, the SGAs did not separate out robustly from the FGAs with respect to overall efficacy and times to treatment discontinuation. However, because of relatively high discontinuation rates across all treatment arms, potential biases regarding optimal dosing of individual drugs, and clear differences in treatment-emergent side effect profiles, the implications of CATIE are subject to interpretation which may preclude definitive guidance in developing pharmacotherapy guidelines for patients with schizophrenia as a whole.
- The efficacy of asenapine in the treatment of schizophrenia in adults was evaluated in 4 published, randomized, DB, PC, and active-controlled (haloperidol, risperidone, and olanzapine) trials, ranging in duration from 6 weeks to 1 year

(Kane et al 2011, Kane et al 2010[a], Potkin et al 2007, Schoemaker et al 2010). Asenapine was associated with statistically significant improvement in PANSS scores from baseline compared to placebo, starting from week 2 of therapy. CGI-I and CGI-S scores were also significantly improved with asenapine therapy compared to placebo. Moreover, an extension study demonstrated a reduced risk of relapse associated with continuation of asenapine therapy (Kane et al 2011). However, a direct-comparison study suggests that asenapine is less effective than olanzapine in terms of changes from baseline in PANSS and CGI-S scores. Furthermore, study discontinuation due to inadequate efficacy was noted in only 14% of patients receiving olanzapine compared to 25% of patients in the asenapine group. Mean weight gain was 0.9 kg with asenapine and 4.2 kg with olanzapine (Shoemaker et al 2010). In another study, while 17% of patients receiving risperidone experienced a weight gain of at least 7% from baseline, 9% of patients in the asenapine group were noted to exhibit clinically significant weight gain (Potkin et al 2007).

- The approval of Secuado was based on the unpublished HP-3070-GL-04 clinical trial (N = 614), a 6-week, Phase 3, DB, PC, multinational, inpatient RCT. Patients with schizophrenia in an episode of acute exacerbation lasting  $\leq 8$  weeks and length of hospitalization  $\leq 21$  days were randomized to receive Secuado 3.8 mg (n = 204), Secuado 7.6 mg (n = 204), or placebo (n = 206) transdermal system once daily. Compared to placebo, both doses of Secuado demonstrated statistically significant improvements in PANSS total score (p < 0.001 for 3.8 mg; p = 0.003 for 7.6 mg) and CGI-S (p < 0.001 for both doses) (FDA Secuado review 2020, Secuado prescribing information 2019).
- The safety and efficacy of brexpiprazole was evaluated in 2 DB, PC, 6-week trials in adults with schizophrenia. In the pivotal studies, brexpiprazole 2 mg and 4 mg daily doses significantly reduced the PANSS score (-20.73 and -19.65 vs -12.01 points with placebo), the primary endpoint, compared with placebo; however, in the BEACON trial, only the brexpiprazole 4 mg dose significantly reduced the PANSS score (-20 vs -13.53 points with placebo) (Correll et al 2015; Kane et al 2015[a]). The most common adverse reactions in MDD trials were akathisia (NNH, 15), increased weight (NNH, 20) and somnolence (NNH, 22); in schizophrenia trials, the most common adverse effects were increased weight (NNH, 48) and tremor (NNH, 51) (Correll et al 2015, Kane et al 2015[a], Thase et al 2015[b]). The safety and efficacy of brexpiprazole for maintenance therapy of schizophrenia was evaluated in a randomized, DB, MC, PC trial. It enrolled 524 patients with an acute exacerbation of psychotic symptoms to be stabilized on brexpiprazole 1 to 4 mg daily. Patients who achieved stabilization (criteria including PANSS total score  $\leq 70$ , CGI-S score  $\leq 4$  [moderately ill], no current suicidal behavior, or violent or aggressive behavior) for 12 weeks then entered a 52-week maintenance phase where they were randomized to their stabilization dose of brexpiprazole (N = 97) or placebo (N = 105). The co-primary endpoints were time to exacerbation of psychotic symptoms or impending relapse, defined as worsening of CGI-I and PANSS scores, hospitalization due to worsening of psychotic symptoms, suicidal behavior, or violent/aggressive behavior. In the maintenance phase, 13.5% of patients in the brexpiprazole group experienced impending relapse vs 38.5% of placebo patients (p < 0.0001) and time to impending relapse was statistically significantly lower (hazard ratio [HR], 0.34; p = 0.0008). However, based on results of an interim analysis, the trial was terminated early. Only a small number of patients were exposed to brexpiprazole for the prescribed 52 weeks and, therefore, conclusions cannot be drawn for long-term use (Fleischhacker et al 2016).
- The efficacy and safety of cariprazine in schizophrenia were demonstrated in 3 DB, randomized, PC, 6-week trials (Durgam et al 2014, Durgam et al 2015[b], Kane et al 2015[b]). A total of 1792 adult patients with acute exacerbation of schizophrenia were administered placebo or cariprazine 1.5 to 9 mg per day. Two trials were fixed-dose studies and included active comparators, risperidone 4 mg and aripiprazole 10 mg, to assess sensitivity; one study was a flexible-dose study with no active comparator. In the flexible-dose study, the mean daily dose ranged from 5 to 8 mg per day (Kane et al 2015[b]). All doses were superior to placebo in reducing PANSS and CGI-S scores and a significant PANSS reduction was observed as soon as 7 days for the higher doses and 2 to 3 weeks for the lower doses (FDA/CBER summary review 2015). Of note, higher doses do result in quicker control of symptoms; however, if high doses continue resulting in accumulation of the active metabolite DDCAR, it is not clear how this may influence safety results. Delayed incidences of akathisia occurred. According to pooled analysis (n = 1317 cariprazine-treated patients) within the FDA clinical summary, the most common adverse events reported in schizophrenia trials were EPS (28.5%) and akathisia (11.2%) (FDA/CBER summary review 2015). The akathisia observed at cariprazine doses  $\leq 6$  mg is comparable to those observed with aripiprazole, but accumulation of the DDCAR metabolite may result in later-onset effects. In schizophrenia studies, 4% of patients with normal hemoglobin A1c developed elevated levels ( $\geq 6.5\%$ ). The proportion of patients with weight increase  $\geq 7\%$  from baseline ranged from 8 to 17% across cariprazine doses. In an OL 48-week extension (N = 97) of a 6-week trial, safety and tolerability were found to be maintained. The most common adverse events were akathisia (14%), insomnia (14%), and weight gain (11.8%) (Durgam et al 2014, Durgam et al 2017). Another study evaluated cariprazine for maintenance therapy for schizophrenia relapse in 765 patients. A



flexible-dose, OL, 8-week, run in phase was followed by a 12-week, fixed-dose, stabilization phase. Patients completing the OL phase (N = 264) entered a DB phase and received cariprazine (3 to 9 mg/day), or placebo for up to 72 weeks. During the DB phase, 24.8% of the cariprazine group experienced relapse vs 47.5% of the placebo group (HR, 0.45; 95% CI, 0.28 to 0.73). Time to relapse was statistically significantly longer for the cariprazine group vs placebo (25<sup>th</sup> percentile time to relapse, 224 vs 92 days, respectively;  $p < 0.001$ ). The long-term safety profile of cariprazine was found to be consistent with findings from previous trials (*Durgam et al 2016*).

- Iloperidone has been studied as monotherapy for the treatment of adults with an acute or subacute exacerbation of schizophrenia. Three 6-week, randomized, DB, placebo- and active comparator (risperidone and haloperidol)-controlled studies found iloperidone to be significantly more effective than placebo (*Potkin et al 2008*). Another 4-week, placebo- and active comparator- (ziprasidone) controlled study found a significant improvement in PANSS scores with iloperidone therapy compared to placebo (*Cutler et al 2008*). Two MAs of these 4 studies corroborated earlier data, finding iloperidone more effective than placebo in terms of improvement from baseline in various subscales of the PANSS scale and BPRS scores (*Citrome et al 2011, Citrome et al 2012*). The long-term efficacy and safety of iloperidone in the treatment of schizophrenia was evaluated in an MA that pooled the follow-up data (up to 52 weeks) from 3 prospective RCTs. The MA found the long-term efficacy of iloperidone, assessed via the time to relapse endpoint, to be comparable to haloperidol ( $p = 0.85$ ), with a more favorable long-term safety profile (*Kane et al 2008*). Moreover, another MA designed to evaluate the short-term safety of iloperidone found the following dose-related adverse effects: dry mouth, dizziness, somnolence and dyspepsia. EPS was noted in association with iloperidone but was more common with haloperidol and risperidone therapies. Iloperidone was also associated with QTc prolongation and weight gain (1.5 to 2.1 kg) (*Weiden et al 2008*). The efficacy of iloperidone for relapse-prevention during maintenance phase of schizophrenia treatment was evaluated in a DB, PC, randomized withdrawal study. Patients were not blinded and were stabilized for 24 weeks. If clinically stable for 12 weeks, they were then randomized to iloperidone (8 to 24 mg/day) (N = 153) or placebo (N = 150) for 26 weeks. The primary endpoints were time to relapse and proportion of patients experiencing relapse (defined as hospitalization due to worsening schizophrenia, worsening of PANSS and CGI-I scores, suicidal or aggressive behavior, or treatment escalation [ie, dose increases or additional medications]). The trial was stopped early due to superior iloperidone relapse prevention. Time to relapse was statistically significantly longer with iloperidone vs placebo (140 vs 95 days, respectively;  $p < 0.0001$ ). The relapse rate for placebo was 64% vs 17.9% for iloperidone ( $p < 0.0001$ ). The safety was comparable to other trial results, with dizziness, insomnia, headache, dry mouth, and somnolence being the most common adverse events. Weight gain  $\geq 7\%$  occurred in 25.2% of iloperidone-treated patients in the relapse-prevention phase. Mean change in QTcF from baseline was 4.9 ms in the iloperidone group (vs 1 ms in placebo) during the relapse-prevention phase. Rates of EPS (2.5% in stabilization phase/1.3% in relapse-prevention phase) and akathisia (3.7% and 1%, respectively) were consistently low in iloperidone-treated patients as well (*Weiden et al 2016*).
- Lumateperone was evaluated in a Phase 2 and two Phase 3 PC trials. All 3 trials enrolled patients who had demonstrated prior response to antipsychotic drug therapy (ie, not treatment-naïve and not treatment-resistant) who were experiencing an acute exacerbation of psychosis starting within the previous 4 weeks.
  - The Phase 2 trial (Study 005) was a 4-week RCT enrolling 335 patients (*Lieberman et al 2016*). Patients received lumateperone 42 mg daily (the marketed dose), lumateperone 84 mg daily, risperidone 4 mg daily, or placebo.
    - The primary endpoint was the change in total score on the PANSS. Results on the PANSS demonstrated LS mean changes of -7.4, -13.2, -8.3, and -13.4 in the placebo, lumateperone 42 mg, lumateperone 84 mg, and risperidone 4 mg groups, respectively. The difference between lumateperone 42 mg and placebo was -5.8 (95% CI, -10.5 to -1.1; multiplicity-adjusted  $p = 0.04$ ), which was larger than that of the higher dose tested and comparable to that of risperidone.
  - The first Phase 3 trial (Study 301) was a 4-week RCT enrolling 450 patients (*Correll et al 2020*). Patients received lumateperone 42 mg daily, lumateperone 28 mg daily, or placebo.
    - Results for the PANSS total score (the primary endpoint) demonstrated LS mean changes of -10.3, -14.5, and -12.9 in the placebo, lumateperone 42 mg, and lumateperone 28 mg groups, respectively. The difference between lumateperone 42 mg and placebo was -4.2 (95% CI, -7.8 to -0.6; multiplicity-adjusted  $p = 0.05$ ).
    - The key secondary endpoint was the change in the CGI-S score. Results demonstrated LS mean changes of -0.5 for the placebo group and -0.8 for both lumateperone groups. The difference between lumateperone 42 mg and placebo was -0.3 (95% CI, -0.5 to -0.1; multiplicity-adjusted  $p = 0.05$ ).

- The other Phase 3 trial (Study 302) enrolled 696 patients (*FDA Caplyta multidisciplinary review 2019*). It had a similar design to the previous studies but had a duration of 6 weeks rather than 4 weeks. Patients received lumateperone 42 mg, lumateperone 14 mg, risperidone 4 mg, or placebo.
  - Results on the PANSS total score did not demonstrate a statistically significant efficacy benefit for either lumateperone dose vs placebo, with differences of 0.5 (95% CI, -2.9 to 3.8) and 0.1 (95% CI, -3.4 to 3.5) for the 42 mg and 14 mg doses, respectively. A significant difference for risperidone vs placebo was demonstrated (-5.4 [95% CI, -8.9 to -1.9]).
  - Results for secondary endpoints were not reported; the FDA reviewers deemed them irrelevant for discussion based on failure of the primary endpoint.
- Lurasidone was investigated for the treatment of adult patients with acute and chronic symptoms of schizophrenia in 2 PC, 6-week studies and two 21-day studies directly comparing the safety and efficacy of lurasidone 120 mg once daily with ziprasidone 80 mg twice daily. In PC studies, lurasidone 40, 80, or 120 mg once daily was associated with significant improvements from baseline in PANSS and the BPRS scores, compared to placebo (*Meltzer et al 2011, Nakamura et al 2009*). The 2 direct-comparison studies demonstrated comparable improvements in the lurasidone and ziprasidone groups in terms of the reduction in total PANSS, PANSS positive symptom, PANSS general symptom, CGI-S scores, and several cognition scales. Likewise, the 2 groups were comparable in terms of rates of discontinuation for any reason and discontinuation due to adverse events (*Harvey et al 2011, Potkin et al 2011*). Of note, lurasidone was more effective in improving negative symptom PANSS scores compared to ziprasidone ( $p = 0.046$ ). Both therapies were associated with a small weight loss from baseline and neither therapy was associated with a clinically significant electrocardiogram abnormality. Extrapyramidal adverse events were noted in 3.3% of patients in the ziprasidone group and in 3.3% of patients receiving lurasidone (*Potkin et al 2011*). The efficacy of lurasidone in maintenance treatment was evaluated in a DB, PC, RCT. Patients (N = 676) with schizophrenia experiencing an acute exacerbation entered into an OL stabilization phase for 12 to 24 weeks. Patients achieving stabilization for 12 weeks (N = 285) were randomized into a 28-week, DB phase to receive lurasidone (40 to 80 mg/day) or placebo. The probability of relapse at the 28-week point was 42.2% vs 51.2% in the lurasidone and placebo groups, respectively (NNT = 12). Lurasidone statistically significantly delayed the time to relapse vs placebo ( $p = 0.039$ ). In patients receiving lurasidone in both the OL and DB phases, the most common adverse events were akathisia (16.7%), insomnia (12.5%), and headache (11.8%) (*Tandon et al 2016*).

### Parkinson's Disorder Psychosis

- Pimavanserin is the only oral atypical antipsychotic FDA-approved for the treatment of hallucinations and delusions associated with PD psychosis. The FDA-approval of pimavanserin was based on a 6-week PC, DB, RCT of 199 patients evaluating the safety and efficacy of pimavanserin 40 mg once daily. Compared to placebo, the least-squares mean difference of total PD adapted SAPS (SAPS-PD) score change from baseline at day 43 favored pimavanserin 40 mg (-3.06; 95% CI, -4.91 to -1.20;  $p = 0.0014$ ). The most common adverse events in the pimavanserin vs the placebo group included urinary tract infection (13 vs 12%), falls (11 vs 9%), peripheral edema (7 vs 3%), hallucinations (7 vs 4%), nausea (6 vs 6%), confusion (6 vs 3%), and headache (1 vs 5%) (*Cummings et al 2014*).
- One MA of pimavanserin included 4 RCTs measuring the efficacy and safety compared to placebo in patients with PD psychosis. Pimavanserin was associated with a significant decrease in SAPS-hallucination and delusions score compared to placebo (weighted mean differences [WMD], -2.26; 95% CI, -3.86 to -0.67;  $p = 0.005$ ). Adverse effects were not significantly different from placebo, except pimavanserin was associated with a significantly lower incidence of orthostatic hypotension (RR, 0.33; 95% CI, 0.15 to 0.75;  $p = 0.008$ ) (*Yasue et al 2016, Bozymski et al 2017*).
- In a more recent MA, pimavanserin significantly improved CGI-S score vs placebo (-0.5; 95% CI, -0.9 to -0.2) in patients with PD psychosis; change in motor function based on the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) did not reach statistical significance (0.2; 95% CI, -1.4 to 1.9) (*Iketani et al 2020*). Other agents included in this MA are not FDA-approved for PD psychosis.

### Long-Acting Injectable Atypical Antipsychotics:

#### Bipolar Disorder

- Risperdal Consta (risperidone microspheres) and Abilify Maintena (aripiprazole ER) are the only long-acting injections FDA-approved for bipolar I disorder in adults.
  - Abilify Maintena (aripiprazole ER) long-acting injection is indicated as maintenance monotherapy treatment (*Calabrese et al 2017*).

- Risperdal Consta (risperidone microspheres) long-acting injection is indicated as monotherapy or in combination with lithium or valproate for maintenance therapy. Compared to placebo, risperidone long-acting injection has demonstrated superior efficacy in acute and non-acute patients with similar safety effects to that of oral risperidone (*Macfadden et al 2009, Quiroz et al 2010, Vieta et al 2012, Yatham et al 2007*).
- In a DB, PC, 52-week randomized withdrawal study (N = 266), aripiprazole ER injection significantly delayed recurrence of any mood episode compared with placebo, with a 55% reduction in risk of experiencing a mood episode over 1 year (HR, 0.45; 95% CI, 0.3 to 0.68). The proportion of patients experiencing recurrence of a manic episode was significantly less with aripiprazole ER injection (9.1% vs 30.1%); however, the recurrence rate for either depressive or mixed episodes was not different between treatment groups. After acute treatment of a manic episode with oral aripiprazole and transition to monotherapy with aripiprazole ER 400 mg intramuscularly (IM) once every 4 weeks (reduction to 300 mg was allowed for adverse reactions) for a 12-week stabilization period, patients were randomized to continue aripiprazole IM or withdrawal to placebo for 52 weeks. Of note, a large proportion of patients did not complete the study. Of the 266 randomized patients, 48.1% (N = 64) of the aripiprazole group and 28.6% (N = 38) of the placebo group completed the study. Treatment-emergent adverse effects that lead to discontinuation more commonly occurred with placebo (25.6 vs 17.4%); those that occurred more often with aripiprazole included weight gain of 7% or greater (18 vs 12.9%), akathisia (21.2 vs 12.8%), and anxiety (6.8 vs 4.5%) (*Calabrese et al 2017*).
- For maintenance therapy, risperidone long-acting injection monotherapy has demonstrated inconsistent results regarding the endpoint of delayed time to recurrence of any mood episode compared to placebo (*Quiroz et al 2010, Vieta et al 2012*). When risperidone long-acting injection was used in combination with mood stabilizers (eg, lithium and valproate), antidepressants, or anxiolytics, the time to relapse was significantly longer with fewer proportions of patients relapsing compared to placebo (*Macfadden et al 2009*). An exploratory post hoc analysis showed that the time to recurrence of any mood episode was also significantly longer with oral olanzapine compared with risperidone long-acting injection (p = 0.001) (*Vieta et al 2012*). The adverse effect profile of long-acting injection therapy is not fully understood; however, EPS, weight gain, hyperprolactinemia, and cardiovascular events were observed in risperidone long-acting injection therapy trials (*Macfadden et al 2009, Quiroz et al 2010, Vieta et al 2012, Yatham et al 2007*).

### Schizophrenia

- All 8 long-acting injectable atypical antipsychotics are FDA-approved for the treatment of schizophrenia in adults. These agents include Abilify Maintena (aripiprazole ER), Aristada and Aristada Initio (aripiprazole lauroxil), Zyprexa Relprevv (olanzapine pamoate ER), Invega Sustenna (paliperidone palmitate once-a-month injection), Invega Trinza (paliperidone palmitate once-every-3-months injection), Risperdal Consta (risperidone microspheres), and Perseris (risperidone once-a-month injection). Invega Sustenna is the only agent FDA-approved for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.
- A number of MAs and SRs have been conducted evaluating long-acting injection atypical antipsychotics compared to oral antipsychotics for the treatment of schizophrenia. Comparative effectiveness data between long-acting injectable atypical antipsychotics are lacking, and there is insufficient evidence to draw firm conclusions. The most recent, well-designed MAs have been summarized for efficacy and safety evaluations.
- One MA of atypical antipsychotics included 13 RCTs measuring the efficacy and safety of long-acting injection atypical antipsychotics vs oral antipsychotics or placebo in patients with schizophrenia. Long-acting injectable atypical antipsychotics were not associated with a significant decrease in the PANSS total score from baseline from oral antipsychotics (p = 0.33); therefore, both formulations had similar efficacy. No additional significant differences were noted. The long-acting injectable atypical antipsychotics were associated with a higher incidence of EPS compared to placebo (p < 0.001) and oral antipsychotics (p = 0.048) (*Fusar-Poli et al 2013*).
- One SR and MA of long-acting antipsychotic injectable agents (including typical and atypical agents) measured the safety and efficacy of treatment compared to oral antipsychotics in 21 RCTs (11 trials measured atypical antipsychotic agents). Patients with schizophrenia, schizophreniform, or schizoaffective disorder were evaluated in longer duration trials of greater than or equal to 6 months. Long-acting injectable antipsychotics were similar to oral antipsychotics for relapse prevention in outpatient studies lasting ≥ 1 year (RR, 0.93; 95% CI, 0.71 to 1.07; p = 0.03). Among individual long-acting injectable antipsychotics, only fluphenazine was superior to oral antipsychotics in drug efficacy (p = 0.02) and in preventing hospitalization (p = 0.04). There was no difference between each individual long-acting injectable antipsychotic and pooled long-acting injectable antipsychotics compared to oral antipsychotics regarding discontinuation due to adverse events (p = 0.65) (*Kishimoto et al 2014*).

- One MA compared outcomes for once-monthly long-acting injections of paliperidone palmitate and risperidone across 7 RCTs. Paliperidone palmitate was less likely to show no improvement in global state (defined as reduction in PANSS scores) vs placebo (RR, 0.79; 95% CI, 0.74 to 0.85). When comparing both active treatments, one trial favored paliperidone palmitate and one trial favored risperidone long-acting injection; therefore, conclusions could not be made. In terms of safety, paliperidone palmitate and risperidone long-acting injection were similar. Compared to placebo, paliperidone palmitate led to significant elevations in serum prolactin, regardless of patient gender (*Nussbaum et al 2012*).
- One SR of 41 trials measuring safety concluded that long-acting injectable atypical antipsychotics are associated with similar adverse effects to that of oral formulations, and no clinically significant trends can be conclusively drawn. Data suggested that olanzapine pamoate was associated with dose-dependent weight gain, lipid and glucose metabolism issues, and may increase prolactin levels even at low doses. Post-injection syndrome, due to accidental intravascular injection of olanzapine pamoate, was characterized by delirium and/or excessive sedation (incidence, 1.2%). The risperidone long-acting injection may increase the risk of QT prolongation, although the clinical significance is unknown. Hyperprolactinemia, EPS, cardiovascular events (ie, tachycardia and orthostatic hypotension), and weight gain are known side effects of risperidone long-acting injection and paliperidone palmitate. The most common adverse event associated with paliperidone palmitate was worsening of psychotic symptoms (incidence, 3.5 to 16%) (*Gentile et al 2013*).
- Recently-approved long-acting injectable agents include Aristada and Aristada Initio (aripiprazole lauroxil), Invega Trinza (paliperidone palmitate once-every-3-months injection), and Perseris (risperidone once-a-month injection).
  - The safety and efficacy of aripiprazole lauroxil in adult patients with schizophrenia was established in one PC, DB, RCT of 622 patients over a period of 12 weeks. Oral aripiprazole was administered concomitantly for the first 3 weeks of treatment. The PANSS total score was significantly decreased at day 85 by 10.9 with monthly IM injections of aripiprazole lauroxil 441 mg and by 11.9 with 882 mg IM monthly compared with placebo ( $p < 0.001$  for both). PANSS was significantly improved as early as day 8 and maintained throughout the study. In terms of safety, more than double the proportion of patients taking aripiprazole lauroxil experienced akathisia (441 mg, 11.6%; 882 mg, 11.5%) compared to placebo (4.3%). The majority of the akathisia (75%) was experienced before the second injection within the first 3 weeks. Additional treatment-emergent adverse effects (incidence  $\geq 2\%$ ) included insomnia, headache, and anxiety (*Meltzer et al 2015*). In an indirect comparison of aripiprazole lauroxil (441 or 882 mg) and aripiprazole ER injection (400 mg), all treatment groups had similar reductions in symptoms of schizophrenia as measured by PANSS total score (*Cameron et al 2018*). The incidence of akathisia and changes in weight were also similar between treatments; although, the occurrence of treatment emergent adverse events was potentially lower with aripiprazole lauroxil 882 mg vs aripiprazole ER injection (OR, 0.46; 95% CI, 0.22 to 0.97).
    - Aristada Initio is indicated only to be used as a single dose in conjunction with oral aripiprazole for the initiation of Aristada, when used for the treatment of schizophrenia in adults. Effectiveness of Aristada Initio was established by adequate and well-controlled studies of oral aripiprazole and Aristada in adult patients with schizophrenia and a single pharmacokinetics bridging study (*Aristada Initio prescribing information 2020*).
  - The FDA-approval of Invega Trinza, the 3-month IM paliperidone palmitate injection, was based on one PC, OL, DB trial of 305 patients with schizophrenia experiencing acute symptoms. Prior to administration of paliperidone palmitate once every 3 months injection, patients were administered flexible oral doses for 17 weeks, and then administered the paliperidone palmitate once monthly injection for 12 weeks. If stable, patients were then administered the once-every-3-months injection. Paliperidone palmitate once-every-3-months injection significantly lengthened the median time to first relapse vs placebo. The mean change in PANSS total scores showed greater improvement in the paliperidone group compared to placebo ( $p < 0.001$ ). Due to the low percentage of relapse in treated patients (7.4%), the median time was not estimated; however, in the placebo group, 23% experienced relapse, with a median time of 274 days. The trial was stopped early due to demonstration of efficacy. Those adverse events noted more frequently in the group receiving paliperidone palmitate vs the placebo group included headache (9 vs 4%), increased weight (9 vs 3%), nasopharyngitis (6 vs 1%), and akathisia (4 vs 1%) (*Berwaerts et al 2015*).
  - The efficacy of risperidone ER monthly injection (Perseris) was evaluated in an 8-week, DB, randomized, PC trial in 354 patients who were experiencing an acute schizophrenia exacerbation. Patients received risperidone 90 mg, 120 mg, or placebo subcutaneously on days 1 and 29. LS mean change from baseline in PANSS total score (the primary outcome) was significantly greater with risperidone 90 mg (-6.148,  $p = 0.004$ ) and 120 mg (-7.237,  $p < 0.001$ ) compared to placebo. Compared to placebo, CGI-S scores were also significantly decreased in both

risperidone dose groups ( $p = 0.0002$  and  $p < 0.0001$ , respectively). Adverse effects were similar between groups, with the exception of weight gain (13% in the risperidone 90 mg group, 12.8% in the risperidone 120 mg group, and 3.4% in the placebo group) (Nasser *et al* 2016).

- The AHRQ conducted an SR of 71 studies on the pharmacological and psychosocial treatment for schizophrenia. Most evidence was for older SGAs, with clozapine, olanzapine, and risperidone superior on more outcomes than other SGAs. Older SGAs were similar to haloperidol on benefit outcomes but had fewer adverse event outcomes. Additionally, results from a subgroup analysis found that that patients experiencing a first episode of schizophrenia did not show significant differences in response or remission when treated with olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, or paliperidone (McDonagh *et al* 2017).
- A SR and MA of 402 RCTs ( $N = 53,463$ ) evaluated the comparative efficacy of 32 antipsychotics for the treatment of adults with multi-episode schizophrenia. For the majority of medications, treatment was associated with a statistically significant reduction in overall symptoms vs placebo, and there were few significant differences between drugs. clozapine, olanzapine, and risperidone exhibited greater efficacy in reducing negative symptoms than many other antipsychotic medications for overall symptoms, with the greatest benefit noted with clozapine. Overall, the authors concluded that antipsychotics vary more in side effect profile than efficacy, thus choice of medication should be individualized for each patient (Huhn *et al* 2019).

## CLINICAL GUIDELINES

- The use of these agents for the treatment of schizophrenia is recognized by national and international guidelines as a mainstay in therapy. Guidelines vary by indication and the following outlines use in children, adolescents, and adults:  
Adults
  - Bipolar disorders
    - The 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guideline recommends: lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine monotherapy or in combination as first line treatments for acute mania. Quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine are recommended first line for bipolar 1 depression. When initiating or switching during maintenance phase, lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination should be considered first-line (Yatham *et al* 2018).
    - The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders (acute and long term treatment of mixed states in bipolar disorder) suggest that the best evidence for manic symptoms in bipolar mixed states is with olanzapine. For depressive symptoms, the addition of ziprasidone may be beneficial; however, the evidence is much more limited than for the treatment of manic symptoms. For maintenance treatment, olanzapine, quetiapine, valproate and lithium can be considered (Grunz *et al* 2017).
  - MDD – The Veteran Administration and Department of Defense (VA/DoD) clinical practice guideline for the management of MDD and the American Psychiatric Association (APA) guideline for the treatment of patients with MDD indicate for the majority of patients, an SSRI, SNRI, bupropion or mirtazapine is optimal for first-line treatment (APA 2010, VA/DoD 2016). The American College of Physicians (ACP) guideline for the treatment of adult patients with MDD recommends cognitive behavioral therapy or second generation antidepressants (eg, SSRI or SNRI) as first line treatment (Qaseem *et al* 2016). While all 3 guidelines suggest that atypical antipsychotics may be useful to augment antidepressant therapy, the VA/DoD suggests they should be considered only when other strategies have failed because of their significant side effects.
  - Schizophrenia –Per the 2020 APA practice guideline for the treatment of patients with schizophrenia, an evidence-based ranking of atypical antipsychotics or an algorithmic approach to antipsychotic selection is not possible due to the significant heterogeneity in clinical trial designs, the limited number of head-to-head comparisons, and the limited clinical trial data for a number of antipsychotics. The guideline notes that there may be clinically meaningful distinctions in response or tolerability of the various atypicals in an individual patient; however, there is no definitive evidence that one typical or atypical antipsychotic will have consistently superior efficacy compared with another, with the possible exception of clozapine. Specific factors that may influence choice of an atypical antipsychotic include available formulation, drug interactions, pharmacokinetic properties, and adverse effects. The choice of an atypical antipsychotic is based on patient-specific factors such as symptoms, prior treatment response, and benefits and risks of treatment (Keepers *et al* 2020).

- The initial goal of acute treatment with an antipsychotic medication is to reduce acute symptoms, to return individuals to their baseline level of functioning. Maintenance treatment aims to prevent recurrence of symptoms and maximize functioning and quality of life.
- Parkinson's disease psychosis – The American Academy of Neurology (AAN) practice parameter on the treatment of depression, psychosis, and dementia in PD states that clozapine should be considered for the treatment for PD and psychosis, quetiapine may be considered, and olanzapine should not be routinely considered (*Miyasaki et al 2006*).

#### Children and Adolescents

- Use of atypical antipsychotics - According to guidelines from the American Academy of Child and Adolescent Psychiatry (AACAP), prior to the initiation of antipsychotic therapy patients should undergo a thorough diagnostic assessment and evaluation for comorbid medical conditions and concomitant medications. Furthermore, a multidisciplinary plan that includes education and psychotherapy should be established. The prescriber should also have a thorough discussion about the risks and benefits of psychotropic treatment (*Findling et al 2011*).
- Autism Spectrum Disorders (ASD) –
  - AACAP guidelines state that pharmacotherapy may be considered in children with ASD when there is a specific target symptom or comorbid condition. Risperidone and aripiprazole are FDA-approved for irritability associated with autism; other drugs that have been studied include: clonidine, olanzapine, valproic acid, lamotrigine, levetiracetam, clomipramine, amantadine, pentoxifylline (in combination with risperidone), and naltrexone (*Volkmar et al 2014*).
  - The 2019 American Academy of Pediatrics (AAP) guideline for the identification, evaluation, and management of children with ASD suggests that pharmacotherapy is used to help manage coexisting behavioral health disorders (eg, ADHD, mood disorders, or anxiety disorders) and problem behaviors or symptoms causing significant impairment and distress including: aggression, self-injurious behavior, sleep disturbance, mood lability, anxiety, hyperactivity, impulsivity, inattention. The guideline recommends the use of SGAs (aripiprazole or risperidone) to manage irritability and/or aggression in ASD. There less evidence for the use of SGAs in decreasing hyperactivity, thus stimulants are recommended first line (*Hyman et al 2020*).
- Bipolar disorder – According to AACAP guidelines for treatment of children and adolescents with bipolar disorder, pharmacotherapy is the primary treatment for bipolar mania. Standard therapy includes lithium, valproate, and/or atypical antipsychotic agents, with other adjunctive medications used as indicated (*McClellan et al 2007*).
- Schizophrenia – According to the AACAP guidelines, antipsychotics are a primary treatment for schizophrenia spectrum disorders in children and adolescents. The choice of agent is typically based on factors such as FDA-approval status, side effect profile, patient and family preference, and cost (*McClellan et al 2013*).
- Tourette's disorder
  - According to AACAP guidelines for the treatment of children and adolescents with tic disorders, pharmacotherapy should be considered for moderate to severe tics causing severe impairment in quality of life, or when psychiatric comorbidities are present that can also be targeted. Most clinicians use atypical antipsychotics before first-generation agents and some prefer  $\alpha$ -agonists over antipsychotic medications due to the adverse effect profile. Commonly used drugs include risperidone, aripiprazole, and clonidine (*Murphy et al 2013*).
  - The 2019 AAN guideline for the treatment of tics in people with Tourette syndrome and chronic tic disorders (*Pringsheim et al 2019*) recommends:
    - Providing information to families about the natural history of a disorder can help inform treatment decisions (Level A). Tics usually begin in childhood and demonstrate a waxing and waning course. Tics generally peak between 10 to 12 years old, with many children experiencing an improvement in tics in adolescence. Additionally, it is important that clinicians assess for co-morbid conditions that are common in people with TS, including attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and other psychiatric disorders (eg, anxiety, mood).
    - Treatment options for tics include: watchful waiting, comprehensive behavioral intervention for tic (CBIT), and pharmacotherapy.
      - People with tics receiving CBIT are more likely than those receiving psychoeducation and supportive therapy to have reduced tic severity. CBIT is a manualized treatment program consisting of habit reversal training (HRT), relaxation training, and a functional intervention to address situations that sustain or worsen tics.

- The use of antipsychotics is recommended when benefits outweigh the risks. No one drug is recommended over another due to insufficient evidence. Haloperidol, risperidone, aripiprazole, and tiapride (not available in the United States) are probably more likely than placebo to reduce tic severity.

## SAFETY SUMMARY

- Ziprasidone is contraindicated in patients with recent acute myocardial infarction (MI), uncompensated heart failure (HF), and history of QT prolongation, or those taking drugs that have demonstrated QT prolongation. Lurasidone is contraindicated for concomitant use with strong cytochrome (CYP) 3A4 inducers and/or inhibitors. Olanzapine/fluoxetine is contraindicated in patients taking concurrent pimozide or thioridazine due to the potential for QT prolongation, and in patients taking concurrent monoamine oxidase inhibitors due to the potential for serotonin syndrome. Lastly, asenapine is contraindicated in patients with severe hepatic impairment.
- All atypical antipsychotic agents, including pimavanserin, have a boxed warning for increased mortality in elderly patients with dementia-related psychosis. Those agents (ie, aripiprazole, lurasidone, brexpiprazole, quetiapine, quetiapine ER, olanzapine/fluoxetine) indicated for depressive episodes carry a boxed warning for an increased risk of suicidal thoughts and behaviors. Zyprexa Relprevv has a boxed warning for incidences of post-injection delirium and/or sedation syndrome; this agent should not be used in patients with dementia-related psychosis. Lastly, clozapine-containing agents (ie, Clozaril and Versacloz) have a boxed warning for severe neutropenia, orthostatic hypotension, bradycardia, syncope, seizures, myocarditis, and cardiomyopathy.
- The atypical antipsychotics have warnings relating to risks of neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, falls, orthostatic hypotension, leukopenia/neutropenia/agranulocytosis, seizures, cognitive and motor impairment, body temperature dysregulation, suicide, and dysphagia. Additional warnings for various agents include:
  - Aripiprazole: Pathological gambling and other compulsive behaviors and cerebrovascular adverse events in elderly patients with dementia-related psychosis
  - Brexpiprazole: Pathological gambling and other compulsive behaviors.
  - Clozapine-containing products: Eosinophilia, hepatotoxicity, QT prolongation, pulmonary embolism, fever, gastrointestinal hypomotility, and anticholinergic toxicity
  - Iloperidone: QT prolongation, hyperprolactinemia, and priapism
  - Ziprasidone: QT prolongation, severe cutaneous reactions (eg, Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] and Stevens-Johnson syndrome), hyperprolactinemia, and priapism
  - Paliperidone: QT prolongation, hyperprolactinemia, priapism, and potential for gastrointestinal obstruction (due to non-deformable tablet)
  - Lurasidone: Hyperprolactinemia and activation of mania/hypomania
  - Risperidone: Priapism, hyperprolactinemia, increased sensitivity in patients with PD or dementia with Lewy bodies, and recent myocardial infarction or unstable cardiac disease
  - Asenapine: QT prolongation, hyperprolactinemia, and hypersensitivity reactions
  - Quetiapine: QT prolongation, cataracts, hypothyroidism, hyperprolactinemia, increased blood pressure in children and adolescents, leukopenia, neutropenia and agranulocytosis, and anticholinergic effects
  - Olanzapine: DRESS and hyperprolactinemia
  - Pimavanserin: QT prolongation
- Clozapine-containing products and Zyprexa Relprevv are a part of the Risk Evaluation and Mitigation Strategies (REMS) program. Registry, training, and counseling are required as part of both programs (*REMS@FDA 2021*). Clozapine products also require certain laboratory levels prior to prescribing. Zyprexa Relprevv requires patients to be observed in clinic for 3 hours after administration.
  - In September 2015, the FDA made modifications to the clozapine REMS program. The absolute neutrophil count (ANC) requirements were modified to a lower ANC level. Benign ethnic neutropenia (BEN) patients were also included as now eligible for clozapine-treatment (*FDA safety communication [clozapine] 2015*).
- Post-marketing reports of intense urges, particularly for gambling, have been reported in patients taking aripiprazole and brexpiprazole. Other compulsive urges include: sexual urges, shopping, eating or binge eating, and other compulsive behaviors. Dose reductions or stopping aripiprazole and brexpiprazole should be considered.
- In 2018, the FDA completed an analysis of reported postmarketing deaths and serious adverse events with the use of pimavanserin, including those reported to the FDA Adverse Event Reporting System (FAERS). The FDA did not identify any new or unexpected safety findings, or findings inconsistent with the established safety labeling. The FDA's

conclusion was that the benefits of pimavanserin outweighed its risks for patients with hallucinations and delusions of Parkinson's disease psychosis (*FDA Drug Safety and Availability 2018*).

- In assessing the reports of deaths, FDA considered that patients with Parkinson's disease have psychosis, a higher mortality rate due to their older age, advanced Parkinson's disease, and other medical conditions. In FAERS reports that included a cause of death, there was no evident pattern to suggest a drug effect (*FDA Drug Safety and Availability 2018*).
- Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at an increased risk of extrapyramidal and/or withdrawal symptoms. Neonates exposed to fluoxetine, a component of Symbyax, late in the third trimester have developed complications arising immediately upon delivery requiring prolonged hospitalization, respiratory support, and tube feeding. These drugs should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In general, a decision should be made whether to discontinue nursing or to discontinue the antipsychotic drug, taking into account the importance of the drug to the mother. It is recommended that women do not breastfeed during treatment with **clozapine**, iloperidone, **lumateperone**, and olanzapine,.
- Many factors are taken into consideration when prescribing an atypical antipsychotic, including co-morbid conditions and safety risks. Common adverse events observed within the class include EPS, sedation, increased prolactin levels, autonomic effects, metabolic effects, and cardiac risks including the risk of ventricular arrhythmias (QT prolongation). Table 3 outlines the relative adverse event trends observed between the various atypical antipsychotic agents:



**Table 3. Relative adverse event risk observed in trials for atypical antipsychotic agents**

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Cariprazine	Clozapine*	Iloperidone	Lumateperone	Lurasidone	Olanzapine	Paliperidone	Pimvanerin	Quetiapine	Risperidone	Ziprasidone
<b>Sedation</b> – sleepiness	Low	Moderate	Moderate	Moderate	High	Moderate	Low	Moderate	High	Low	Low	High	Moderate	Moderate
<b>Diabetes</b>	Low	Moderate	Low	Low	High	Moderate	Low	Moderate	High	Low	Low	Moderate	Moderate	Low
<b>EPS</b> – akathisia (motor restlessness), parkinsonism (tremor, rigidity, and slow movements), dystonia (continuous muscle spasms or contractions), and tardive dyskinesia (jerky movements)	Low	Low to moderate	Low to moderate	Low to moderate	Low	Low	Low	Moderate	Low to moderate	Moderate	Low	Low	Moderate	Low to moderate
<b>Anticholinergic</b> – blurred vision, constipation, dry mouth, drowsiness, memory impairment, etc.	Low	Low	Low	Moderate	High	Low	Low	Low	Moderate	Low	Low	Moderate	Low	Low
<b>Orthostasis</b> – low blood pressure resulting in dizziness when standing up	Low	Moderate	Low	Low	High	High	Low	Low	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
<b>Weight Gain</b>	Low	Moderate	Low	Moderate	High	Moderate	Low	Low	High	Moderate	Negligible	Moderate	Moderate	Low
<b>Prolactin</b> – high levels linked to gynecomastia, sexual dysfunction, menstrual disruption, acne, amenorrhea, hirsutism, osteoporosis, increased risk of hip fracture, etc.	Low	Moderate	Low	Low	Low	Moderate	Low	Low	Moderate	High	Low	Low	High	Moderate
<b>QT prolongation</b>	Negligible to low	Low	Negligible to low	Negligible to low	Moderate	Low	Negligible to low	Negligible to low	Moderate	Low	Low	Moderate	Moderate	High
<b>Hypercholesterolemia</b>	Low	Moderate	Moderate	Low	High	Low	Low	Moderate	High	Moderate	Low	High	Low	Low

**Abbreviation:** EPS = extrapyramidal side effects

**Note:** Information is based on indirect comparisons and expert assessments; however, more head-to-head trials are warranted to substantiate observations

\*Granulocytopenia or agranulocytosis has been reported in 1% of patients. Clozapine is associated with an excess risk of myocarditis and venous thromboembolism (VTE), including fatal pulmonary embolism (PE).

(Jibson et al 2021)

**DOSING AND ADMINISTRATION**

**Table 4. Dosing and administration**

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Abilify (aripiprazole)	Tablet, tablet with sensor (drug/device), orally disintegrating tablet, oral solution	Oral	Daily  Tablet with sensor has a patch which should be changed weekly or sooner, as needed.	Dose adjustments are recommended in known CYP2D6 poor metabolizers, or with concomitant CYP2D6 inhibitors, and/or CYP3A4 inhibitors/inducers.  The MyCite (tablet with sensor) system is composed of an ingestible event marker (IEM) sensor, MyCite patch (wearable sensor), MyCite app, and a web-based portal for healthcare professionals and caregivers. Tablets with sensor may be administered with or without food. Most ingestions will be detected in 30 minutes to 2 hours. Patients should be instructed not to repeat doses if not detected.
Abilify Maintena (aripiprazole ER)	Injection	IM	Monthly	Must be administered by a healthcare professional.  Dose adjustments are recommended in known CYP2D6 poor metabolizers, or with concomitant CYP2D6 inhibitors, and/or CYP3A4 inhibitors/inducers.
Aristada (aripiprazole lauroxil)			Monthly (441 mg, 662 mg, or 882 mg) or every 6 weeks (882 mg) or every 2 months (1064 mg)	Aripiprazole-naïve patients should establish tolerability with oral formulations prior to initiating long-acting injections.
Aristada Initio (aripiprazole lauroxil)			One dose of Aristada Initio 675 mg and aripiprazole 30 mg orally with the first Aristada injection	
Saphris (asenapine)	Sublingual tablet	Oral	Twice daily	Sublingual tablets should be placed under the tongue and left to dissolve completely; they should not be swallowed.  Eating and drinking should be avoided for 10 minutes after administration.
Secuado (asenapine)	Patch	Transdermal	Daily	Patch should be applied once daily and left in place for 24 hours.
Rexulti (brexpiprazole)	Tablet	Oral	Daily	Dose adjustments are recommended in known CYP2D6 poor metabolizers and in

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
				concomitant CYP3A4 or CYP2D6 inhibitors, and/or strong CYP3A4 inducers.  Dosage adjustments are recommended for hepatic and renal impairment.
Vraylar (cariprazine)	Capsule, therapy pack	Oral	Daily	Dose adjustments are recommended with concomitant CYP3A4 inhibitors. Concomitant use is not recommended with CYP3A4 inducers.  Use of the drug is not recommended in severe hepatic or renal impairment since it has not been studied in these populations.
Clozaril (clozapine)	Tablet	Oral	Once or twice daily	Prior to initiating, a baseline ANC must be $\geq$ 1500/mcL ( $\geq$ 1000/mcL for patients with BEN). To continue treatment, ANC must be monitored regularly.  Dose adjustments are recommended in patients with renal/hepatic impairment, CYP2D6 poor metabolizers, taking concomitant CYP2D6, CYP1A2, CYP3A4 inhibitors and/or CYP3A4, CYP1A2 inducers.
Clozapine	Orally disintegrating tablet			
Versacloz (clozapine)	Suspension			
Fanapt (iloperidone)	Tablet	Oral	Twice daily	Dose adjustments are recommended in patients with hepatic impairment, CYP2D6 poor metabolizers, taking concomitant CYP2D6 and/or CYP3A4 inhibitors.
Caplyta (lumateperone)	Capsule	Oral	Once Daily	Should be administered with food.  Moderate or strong CYP3A4 inhibitors and CYP3A4 inducers; moderate or severe hepatic impairment: Avoid concomitant use.
Latuda (lurasidone)	Tablet	Oral	Daily	Dose adjustment recommended with concomitant use with a moderate CYP3A4 inhibitor and renal/hepatic impairment. Do not use with strong CYP3A4 inhibitors/inducers.  Should be administered with food ( $\geq$ 350 calories).
Zyprexa (olanzapine)	Tablet	Oral	Daily	
Zyprexa Zydys (olanzapine)	Orally disintegrating tablet			

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Zyprexa IntraMuscular (olanzapine)	Injection	IM	As needed; max. 3 doses 2 to 4 hrs apart	
Zyprexa Relprevv (olanzapine ER)	Injection	IM	Every 2 weeks (initial: 210 mg or 300 mg; maintenance: 150 mg, 210 mg, or 300 mg) or every 4 weeks (initial: 405 mg; maintenance: 300 mg or 405 mg)	This product is available only through a restricted distribution program and must be administered by a healthcare professional; patient observation is required for at least 3 hours after injection due to the potential for Post-Injection Delirium/Sedation Syndrome.  Tolerability with oral olanzapine must be established prior to initiating therapy with this long-acting injection.
Symbyax (olanzapine/fluoxetine)	Capsule	Oral	Daily	The safety of doses above 18 mg/75 mg has not been evaluated in clinical studies.  The safety of doses above 12 mg of olanzapine and 50 mg of fluoxetine has not been evaluated in pediatric clinical studies.  Start olanzapine/fluoxetine at 3 mg/25 mg or 6 mg/25 mg in patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine/fluoxetine (female gender, geriatric age, nonsmoking status).
Invega (paliperidone ER)	Tablet	Oral	Daily	Tablets should be swallowed whole and should not be chewed, divided, or crushed.
Invega Sustenna (paliperidone ER)	Injection	IM	Monthly	Must be administered by a healthcare professional.  Dosage adjustment for renal impairment.  For patients naïve to oral paliperidone or oral or injectable risperidone, tolerability with oral paliperidone or oral risperidone must be established prior to initiating therapy with this long-acting injection.
Invega Trinza (paliperidone ER)	Injection	IM	Every 3 months	Must be administered by a healthcare professional.  Prior to initiation, patients must have been adequately treated with Invega Sustenna for at least 4 months.  Dosage adjustment for renal impairment.

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Nuplazid (pimavanserin)	Tablet, capsule	Oral	One 34 mg capsule once daily; or one 10 mg tablet with strong CYP3A4 inhibitors	No initial dosage titration. Dosage adjustment is required with concomitant use with strong CYP3A4 inhibitors; avoid use with strong or moderate CYP3A4 inducers.
Seroquel (quetiapine)	Tablet	Oral	Daily to twice daily	Dosage adjustment for hepatic impairment, geriatric use, and with concomitant CYP3A4 inhibitors and/or inducers.
Seroquel XR (quetiapine ER)	Tablet	Oral	Daily	Tablets should be swallowed whole and not split, chewed, or crushed. Dosage adjustment for hepatic impairment, geriatric use, and with concomitant CYP3A4 inhibitors and/or inducers
Risperdal (risperidone)	Tablet, oral solution	Oral	Daily to twice daily	Dosage adjustment for renal/hepatic impairment.
Risperdal M-Tabs (risperidone)	Orally disintegrating tablet			
Risperdal Consta (risperidone microspheres)	Injection	IM	Every 2 weeks	Must be administered by a healthcare professional.
Perseris (risperidone ER)		SC	Monthly	Tolerability to oral risperidone must be established prior to initiating therapy with this long-acting injection.
Geodon (ziprasidone)	Capsule	Oral	Twice daily	Give capsules with food.
	Injection	IM	As needed; 10 mg every 2 hrs or 20 mg every 4 hrs up to a maximum of 40 mg/day	IM ziprasidone should be administered with caution to patients with impaired renal function as the cyclodextrin excipient is cleared by renal filtration.

See the current prescribing information for full details.

## CONCLUSION

- The antipsychotics are divided into 2 distinct classes: typical antipsychotics, also called FGAs, and atypical antipsychotics, also called SGAs (*Miyamoto et al 2005*).
- There are a number of atypical antipsychotic formulations available as both branded and generic products. These agents are available in various dosage forms including capsules, tablets, injections, oral solutions, sublingual tablets, and orally disintegrating tablets.
- FDA-approved indications for the atypical antipsychotics include irritability associated with autistic disorder, bipolar disorder, Tourette's disorder, MDD, schizophrenia, schizoaffective disorder, and PD psychosis. The indications vary by diagnosis, age, or by use as mono- or adjunctive-therapy. All agents in this class are indicated for use in schizophrenia with the exception of the combination agent Symbyax (olanzapine/fluoxetine) and pimavanserin. Clozapine and paliperidone products, excluding Invega Trinza, are indicated for the treatment of schizoaffective disorder, and clozapine

is the only agent in this class FDA-approved for treatment-resistant schizophrenia. Aripiprazole, lurasidone, olanzapine, quetiapine and risperidone are approved for use in patients  $\geq 13$  years of age and paliperidone oral products are approved for patients  $\geq 12$  years of age with schizophrenia. All oral agents in this class are indicated for use in bipolar disorder, except clozapine, iloperidone, **lumateperone**, paliperidone, pimavanserin, and brexpiprazole. Risperdal Consta and Abilify Maintena are the only long-acting injectables indicated for the treatment of bipolar disorder. Aripiprazole, olanzapine/fluoxetine, risperidone, quetiapine, lurasidone, and asenapine are approved for use in pediatric patients  $\geq 10$  years of age with bipolar disorder. Olanzapine is approved for use in patients  $\geq 13$  years of age with bipolar disorder. Aripiprazole and risperidone are the only agents indicated for the treatment of irritability associated with autistic disorder in pediatric patients (aged 6 to 17 years, and 5 to 17 years, respectively). Aripiprazole is the only agent indicated for the treatment of Tourette's disorder in pediatric patients, aged  $\geq 6$  years. Aripiprazole, brexpiprazole, and quetiapine ER are indicated as adjunctive treatment for MDD in patients already taking an antidepressant. Olanzapine, when prescribed in combination with fluoxetine, is indicated for treatment-resistant depression. Pimavanserin is the only agent in the class FDA-approved for treatment of PD psychosis.

- Comparative effectiveness data are most available for the treatment of schizophrenia and schizophrenia-like psychosis in adults; however, outcomes are often inconsistent. Study evidence demonstrates that there are no consistent differences in the efficacy between the atypical antipsychotics in acute or short-term trials, although clozapine has often been touted as significantly more effective for patients with treatment-resistant schizophrenia compared to all other atypical antipsychotics (*Leucht et al 2013, Lieberman et al 2005, Stroupe et al 2006, Stroupe et al 2009, Huhn et al 2019*). In general, clozapine is often followed by olanzapine and risperidone in terms of improved efficacy (*Leucht et al 2013*). There is also very little evidence evaluating the long-acting injection agents and newer agents brexpiprazole, cariprazine, iloperidone, and lurasidone. Challenges associated with comparative effectiveness reviews are mainly due to high attrition rates, internal validity study concerns, and small sample sizes within trials. **In general, antipsychotics differ more in their side effects than efficacy, thus choice of therapy should be individualized.**
- Each atypical antipsychotic has a distinctive chemical structure, mechanism of action, and neuropharmacologic and adverse event profile. It should be noted that paliperidone is an active metabolite of risperidone and therefore carries some similarity in chemical structure and pharmacologic effects with the parent drug. Plasma levels of cariprazine and its metabolite accumulate over time; adverse reactions may not appear until after several weeks of drug administration.
- Safety profiles vary between agents and are often an important component of treatment selection. The long-acting injection antipsychotics are often prescribed for patients who demonstrate adherence issues with oral formulations. Common adverse events observed within the class include EPS, increased prolactin levels, autonomic effects, metabolic effects, and cardiac risks including risk of ventricular arrhythmias (QT prolongation). When compared to the typical antipsychotics, the atypical antipsychotics are associated with a lower risk of EPS and tardive dyskinesia, making them a generally better-tolerated treatment option (*Abou-Setta et al 2012, Clinical Pharmacology 2021*). However, certain atypical antipsychotic agents appear to have varying levels of risk according to the side effect profile (*Jibson et al 2021*). The following factors may be considered when selecting certain agents in patients:
  - **Metabolic syndrome** – Metabolic effects influencing weight gain, glycemic effects, and lipid profiles have been reported to fluctuate with all atypical antipsychotics. Clozapine and olanzapine have been associated with the highest risks; aripiprazole, lurasidone, and ziprasidone have been associated with lower risks. Despite the stratified risks, routine monitoring of metabolic measures is recommended for patients on all antipsychotics.
  - **EPS or tardive dyskinesia** – Atypical antipsychotics have a lower risk of these side effects compared to typical antipsychotic agents. Tardive dyskinesia risks have been reported to be similar to the prevalence of EPS. Risperidone has been associated with a higher risk of EPS (up to 25% in adults); clozapine and quetiapine carry the lowest risk.
  - **Anticholinergic effects** – Anticholinergic side effects include dry mouth, constipation, blurred vision, and urinary retention. Clozapine has the strongest affinity for muscarinic receptors among the agents in this class review; therefore, anticholinergic side effects are reported most often. This is followed by olanzapine and quetiapine.
  - **QT prolongation** – QT prolongation has been reported with a number of atypical antipsychotic agents, but to a lesser degree than other classes of medications. Iloperidone and ziprasidone have been reported to prolong the QT interval (average increase in QTc of 9 to 10 msec) most often, and should be avoided in high risk patients. Those less likely to cause cardiac arrhythmias include aripiprazole, lurasidone, and cariprazine; however, very few studies have been conducted with lurasidone and cariprazine.
  - **Myocarditis and cardiomyopathy** – Clozapine has been associated with fatal cases, often within the first few months of treatment.

- Orthostatic hypotension and tachycardia – Changes in heart rate and blood pressure are most frequently observed with clozapine (9% to 25%) and iloperidone (3% to 12%). In pediatric patients, quetiapine has been associated with increased systolic/diastolic pressure in 15% to 41% of patients, but in adults orthostatic hypotension and tachycardia have been reported in up to 7% of patients. Tachycardia has been reported in up to 16% of paliperidone-treated adult patients. Hypotension has been reported less frequently with aripiprazole, asenapine, brexpiprazole, cariprazine, lurasidone, and pimavanserin. However, fewer studies have been conducted with the newer agents.
- Seizure – All atypical antipsychotics carry a risk for seizures; however, this appears to be associated with lowering the seizure threshold vs new-onset seizures. Incidences of seizure are most often reported with clozapine (3% to 5%), and to a lesser degree risperidone (0.3%).
- Prolactin levels and sexual side effects – Elevations of prolactin have been most associated with risperidone and paliperidone. This is particularly concerning in pediatric patients as it is associated with changes in estrogen and testosterone levels and may result in gynecomastia and menstrual disturbances. In pediatric patients administered risperidone, hyperprolactinemia has been reported in 49% to 87% of patients versus adults in which incidences range from 1% to 4% depending on formulation (IM or oral routes). Abnormal prolactin levels have also been associated with sexual dysfunction, infertility and galactorrhea. Of the atypical antipsychotics that are well studied, prolactin abnormalities are less frequently reported with olanzapine and ziprasidone. For patients in which sexual dysfunction is a concern, a number of MAs have referred to aripiprazole as the drug of choice (*Serretti et al 2011*).
- Sedation – Clozapine is most associated with sedation (46%), followed by olanzapine (20% to 52%) and quetiapine (18% to 57%). In this class, aripiprazole is unique as insomnia was reported in  $\geq 10\%$  of adult patients, but somnolence/fatigue and insomnia were reported in  $\geq 10\%$  of pediatric patients.
- Agranulocytosis – Agranulocytosis, leukopenia, and neutropenia are associated with use of clozapine. Within the first few months of treatment, this is particularly evident in patients with pre-existing low blood counts or those who had prior drug-induced blood dyscrasias.
- Hypersensitivity – Olanzapine and ziprasidone have a specific warning for a fatal drug reaction with eosinophilia and systemic symptoms or DRESS. Asenapine has a warning for hypersensitivity reactions.
- Cariprazine, has demonstrated safe and effective use in doses  $\leq 6$  mg/day for the treatment of bipolar disorder or schizophrenia in short-term adult trials (*Calabrese et al 2015*, *Durgam et al 2015[a]*, *Durgam et al 2014*, *Durgam et al 2015[b]*, *Earley et al 2020*, *FDA/CBER summary review 2015*, *Kane et al 2015[b]*, *Sachs et al 2015*). The most common adverse events with treatment are EPS and akathisia. The clinical implications of the long half-life have not been well characterized and some experts have cited safety concerns associated with the accumulating active metabolite. One 72-week (N = 264) and one 48-week (N = 97) extension trial in patients with schizophrenia have demonstrated comparable results to short-term trials of 6 weeks. Patients who are able to persist on treatment maintained efficacy and tolerability at cariprazine doses of 1.5 mg to 9 mg daily during maintenance therapy (*Durgam et al 2016*, *Durgam et al 2017*).
- For the treatment of Tourette's disorder, aripiprazole has demonstrated safe and effective use compared to placebo in trials of 8 to 10 weeks in pediatric patients aged  $\geq 6$  years. Adverse events most frequently observed included sedation-like effects, nausea, headache, nasopharyngitis, and increased appetite (*Abilify prescribing information 2020*, *Gulisano et al 2011*, *Yoo et al 2013*).
- For the treatment of irritability associated with autism, one small, low quality study (N = 59) compared the effects of aripiprazole and risperidone in patients aged 4 to 18 years over a period of 8 weeks, although FDA-approval stipulates therapy should be initiated for ages 5 to 6 years. No differences were detected in terms of safety or efficacy; however, the ABC-I scores numerically favored risperidone ( $p = 0.06$ ) (*Ghanizadeh et al 2014*). Both agents have demonstrated safe and effective use in PC trials (*Marcus et al 2009*, *McCracken et al 2002*, *Owen et al 2009*, *Shea et al 2004*, *McDougle et al 2005*). Based on current data, both agents appear to have similar efficacy and safety.
- For the treatment of PD psychosis, pimavanserin has demonstrated safe and effective use compared to placebo. Pimavanserin was associated with a significantly lower incidence of orthostatic hypotension (*Cummings et al 2014*, *Yasue et al 2016*, *Bozymski et al 2017*).
- For the treatment of MDD, aripiprazole, brexpiprazole, and quetiapine ER have demonstrated effectiveness when combined with adjunctive treatment, generally in trials with a 6-week duration and combined with an SSRI or SNRI. Olanzapine/fluoxetine (Symbyax) has also demonstrated effectiveness in treatment-resistant depression. Most studies have been PC trials. Brexpiprazole is the newest agent to be FDA approved; results from RCTs and an MA demonstrate efficacy vs placebo, and the safety profile appears to be similar to aripiprazole (*Thase et al 2015[a]*, *Thase et al 2015[b]*, *Yoon et al 2017*). One MA found all agents were more effective than antidepressant monotherapy in improving response and remission rates, although adjunctive atypical antidepressant therapy was associated with a higher discontinuation

rate due to adverse effects (*Wen et al 2014*). Another MA concluded aripiprazole and quetiapine may have an advantage in reducing remission (NNT, 9) compared to olanzapine/fluoxetine (NNT, 19) (*Spielmann et al 2013*). More well-designed, head-to-head trials are needed to validate conclusions. Treatment was associated with several medication-specific adverse events, including akathisia (aripiprazole), sedation (quetiapine, olanzapine/fluoxetine, and aripiprazole), abnormal metabolic laboratory results (quetiapine and olanzapine/fluoxetine), and weight gain (all drugs, especially olanzapine/fluoxetine).

- For the treatment of bipolar disorder, a number of atypical antipsychotics have demonstrated effective use for managing symptoms associated with manic or mixed episodes; however, only a few agents have demonstrated efficacy for depressive episodes. In adolescents and children, aripiprazole, olanzapine, olanzapine/fluoxetine, risperidone, quetiapine, and asenapine are FDA-approved for manic or mixed episodes, although only quetiapine and olanzapine/fluoxetine have been studied for depressive episodes. An AHRQ SR found that atypical antipsychotics decrease mania, decrease depression symptoms slightly, and improve symptom severity and global functioning to a small extent vs placebo. In addition, they probably increase response and remission rates vs placebo for manic/mixed phases (*Pillay et al 2017*). For depressive episodes, evidence is less clear, but point to efficacy with the FDA approved agents (*Findling et al 2014, Detke et al 2015*). Support for use of atypical antipsychotics in adult patients with bipolar disorder has been demonstrated in several MAs (*Abou-Setta et al 2012, Muralidharan et al 2013, Lindström et al 2017*). Risperdal Consta (risperidone microspheres) and Abilify Maintena are the only long-acting injection agents in this class that have demonstrated safe and effective use (*Calabrese et al 2017, Macfadden et al 2009, Quiroz et al 2010, Vieta et al 2012, Yatham et al 2007*). Although only lurasidone, quetiapine (immediate- and extended-release), and olanzapine/fluoxetine have demonstrated efficacy for depressive episodes, MAs have concluded that olanzapine/fluoxetine may be the optimal treatment compared to other treatment options for depressive episodes (*Fornaro et al 2016, Silva et al 2013, Taylor et al 2014, Vieta et al 2010*).
- For the treatment of schizophrenia, MAs evaluating the roles of available atypical antipsychotics in the treatment of schizophrenia suggest that all agents are significantly more effective than placebo. Most analyses and studies have demonstrated that with the exception of clozapine, the atypical antipsychotics do not separate out robustly from the typical antipsychotics with respect to overall efficacy and times to treatment discontinuation. The trends for respective efficacy suggest that clozapine, olanzapine, and risperidone may be more effective agents based on relapse and remission rates compared to typical antipsychotics or placebo; however, many atypical antipsychotics haven't been studied to the same extent as these agents. In general, due to high attrition rates in trials, validity is limited, thereby making it difficult to make strong conclusions (*Abou-Setta et al 2012, Asenjo Lobos et al 2010, Asmal et al 2013, Cipriani et al 2011, Citrome et al 2009, Durgam et al 2014, Durgam et al 2015[b], Glick et al 2011, Jones et al 2010, Kane et al 2015[b], Khanna et al 2014, Klemp et al 2011, Komossa et al 2009[a], Komossa et al 2010[a], Komossa et al 2009[b], Komossa et al 2010[b], Komossa et al 2011, Kumar et al 2013, Leucht et al 2009[a], Leucht et al 2009[b], Leucht et al 2013, Lieberman et al 2005, Pagsberg et al 2017, Perlis et al 2006[b], Pillay et al 2017, Riedel et al 2010, Stroupe et al 2006, Stroupe et al 2009, Tarr et al 2011, Vieta et al 2010, Yildiz et al 2011*).
- The use of these agents for the treatment of schizophrenia is recognized by national and international guidelines as a mainstay in therapy. Guidelines vary by indication and the following outlines use in children, adolescents, and adults:

#### Adults

- MDD – For the majority of patients, an SSRI, SNRI, bupropion or mirtazapine is optimal for first-line treatment. Atypical antipsychotics may be useful to augment antidepressant therapy (*APA 2010, Qaseem et al 2016, Va/DoD 2016*).
- Bipolar Disorders - recent guidelines from CANMAT/ISBD and WFSBP have recommended clear first line pharmacological therapies for various stages of bipolar disease. These include second generation antipsychotics, lithium, valproate, divalproex and lamotrigine as monotherapy or combination therapy.
- Schizophrenia –Guidelines state that an evidence-based ranking of atypical antipsychotics or an algorithmic approach to antipsychotic selection is not possible due to the significant heterogeneity in clinical trial designs, the limited number of head-to-head comparisons, and the limited clinical trial data for a number of antipsychotics (*Keepers et al 2021*). There may be clinically meaningful distinctions in response or tolerability of the various atypicals in an individual patient; however, there is no definitive evidence that one atypical antipsychotic will have consistently superior efficacy compared with another, with the possible exception of clozapine. Specific factors that may influence choice of an atypical antipsychotic include available formulation, drug interactions, pharmacokinetic properties, and adverse effects.



- Parkinson's disease psychosis – The American Academy of Neurology Practice Parameter on the treatment of depression, psychosis, and dementia in PD states that clozapine should be considered for the treatment for PD and psychosis, quetiapine may be considered, and olanzapine should not be routinely considered (*Miyasaki et al 2006*).
- Children and Adolescents**
- Use of atypical antipsychotics - According to guidelines from the American Academy of Child and Adolescent Psychiatry (AACAP), prior to the initiation of antipsychotic therapy, patients should undergo a thorough diagnostic assessment and evaluation for comorbid medical conditions and concomitant medications. Furthermore, a multidisciplinary plan that includes education and psychotherapy should be established. The prescriber should also have a thorough discussion about the risks and benefits of psychotropic treatment (*Findling et al 2011*).
  - Autism Spectrum Disorders (ASD) –
    - AACAP guidelines state that pharmacotherapy may be considered in children with ASD when there is a specific target symptom or comorbid condition. Risperidone and aripiprazole are FDA-approved for irritability associated with autism; other drugs that have been studied include: clonidine, olanzapine, valproic acid, lamotrigine, levetiracetam, clomipramine, amantadine, pentoxifylline (in combination with risperidone), and naltrexone (*Volkmar et al 2014*).
    - The 2019 (AAP) guideline for children with ASD suggests that pharmacotherapy is used to help manage coexisting behavioral health disorders (eg, ADHD, mood disorders, or anxiety disorders) and problem behaviors or symptoms causing significant impairment and distress including: aggression, self-injurious behavior, sleep disturbance, mood lability, anxiety, hyperactivity, impulsivity, inattention. The guideline recommends the use of SGAs (aripiprazole or risperidone) to manage irritability and/or aggression in ASD. There less evidence for the use of SGAs in decreasing hyperactivity; stimulants are recommended first line.
  - Bipolar disorder – According to AACAP guidelines for treatment of children and adolescents with bipolar disorder, pharmacotherapy is the primary treatment for bipolar mania. Standard therapy includes lithium, valproate, and/or atypical antipsychotic agents, with other adjunctive medications used as indicated (*McClellan et al 2007*).
  - Schizophrenia – According to AACAP guidelines, antipsychotics are a primary treatment for schizophrenia spectrum disorders in children and adolescents. The choice of agent is typically based on factors such as FDA-approval status, side effect profile, patient and family preference, and cost (*McClellan et al 2013*).
  - Tourette's disorder– According to AACAP guidelines for the treatment of children and adolescents with tic disorders, pharmacotherapy should be considered for moderate to severe tics causing severe impairment in quality of life, or when psychiatric comorbidities are present that can also be targeted. Most clinicians use atypical antipsychotics before first-generation agents and some prefer  $\alpha$ -agonists over antipsychotic medications due to the adverse effect profile. Commonly used drugs include risperidone, aripiprazole, and clonidine (*Murphy et al 2013*).
  - Pharmacologic therapy treatment is highly individualized and dependent on a number of patient characteristics and response to treatment. In certain patient groups, such as pediatric patients, liquid formulations are useful for better dose-control, so clinicians may titrate and taper doses in those that may have sensitive responses to treatment. Agents with different chemical structures have different clinical responses and adverse events; therefore, access to the atypical antipsychotic medication class is important in order to tailor therapies to individual patients.

## REFERENCES

- Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; June 2020.
- Abilify Maintena [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; June 2020.
- Abilify MyCite [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; December 2020.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-generation and second-generation antipsychotics in adults: Comparative Effectiveness Review. [Monograph on the internet]. Agency for Healthcare Research and Quality (AHRQ). Rockville, MD. 2012 Aug. No. 63. [https://www.ncbi.nlm.nih.gov/books/NBK107254/pdf/Bookshelf\\_NBK107254.pdf](https://www.ncbi.nlm.nih.gov/books/NBK107254/pdf/Bookshelf_NBK107254.pdf). Accessed April 13, 2021.
- Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. *J Child Adolesc Psychopharmacol*. 2008;18(3):227-236.
- American Psychiatric Association. Diagnostic and Statistical manual of Mental Disorders, 5<sup>th</sup> edition (DSM V). Washington, DC: In Section II, Depressive Disorders and Schizophrenia Spectrum and Other Psychotic Disorders. May 2013.
- American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. October 2010. [http://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/mdd.pdf](http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf). Accessed April 13, 2021.
- Aristada [package insert]. Waltham, MA: Alkermes, Inc.; March 2021.
- Aristada Initio [package insert]. Waltham, MA: Alkermes, Inc.; March 2021.
- Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2010;(11):CD006633.

- Asmal A, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2013;11:CD006625.
- Augustyn M. Autism spectrum disorder: terminology, epidemiology, and pathogenesis. UpToDate website. [www.uptodate.com/](http://www.uptodate.com/). Updated May 4, 2020. Accessed April 13, 2021.
- Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomized, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. *Journal of Affective Disorders*. 2010;127:19-30.
- Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2007;68(6):843-853.
- Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. *JAMA Psychiatry*. 2015;72(8):830-839.
- Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. *CNS Spectrums*. 2005;10(2):141-148.
- Bozymski KM, Lowe DK, Pasternak KM, et al. Pimavanserin: a novel antipsychotic for Parkinson's disease psychosis. *Ann Pharmacother*. 2017;51(6):479-487.
- Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar depression. *Int J Neuropsychopharmacol*. 2009;12:773-782.
- Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, Thao V, Sunderlin B. Treatment for Bipolar Disorder in Adults: A Systematic Review. Comparative Effectiveness Review No. 208. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2012-00016-I.) AHRQ Publication No. 18-EHC012-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2018. doi 10.23970/AHRQEPCCER208
- Calabrese JR, Keck PE, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. *J Clin Psychiatry*. 2015; 76(3):284-292.
- Calabrese JR and Hertel P. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. *J Clin Psychiatry*. 2017;78(3):324-331.
- Cameron C, Zummo Jacqueline, Desai D, et al. Efficacy and safety of aripiprazole lauroxil once monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. *Curr Med Res Opin*. Jan 2018:1-9. doi:10.1080/03007995.2017.1410471.
- Caplyta [package insert]. New York, NY: Intra-Cellular Therapies, Inc.; December 2019.
- Capone GT, Goyal P, Grados M, et al. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. *J Dev Behav Pediatr*. 2008;29:106-116.
- Centers for Disease Control and Prevention (CDC)[a]. Autism and developmental disabilities monitoring (ADDM) network. CDC Web site. <https://www.cdc.gov/ncbddd/autism/addm.html>. Accessed April 8, 2021.
- Centers for Disease Control and Prevention (CDC)[b]. Prevalence of depression among adults aged 20 and over: United States, 2013-2016. CDC Web site. <https://www.cdc.gov/nchs/products/databriefs/db303.htm>. Accessed April 8, 2021.
- Chiesa A, Chierzi F, De Ronchi D, et al. Quetiapine for bipolar depression: a systematic review and meta-analysis. *Int Clin Psychopharmacol*. 2012;27(2):76-90.
- Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet*. 2011;378(9799):1306-1315.
- Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. *Schizophrenia Research*. 2011;131:75-81.
- Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. *Hum Psychopharmacol Clin Exp*. 2012;27:24-32.
- Citrome L. Asemapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. *Int J Clin Pract*. 2009;63(12):1762-1784.
- Clinical Pharmacology website. 2021. <https://www.clinicalkey.com/pharmacology/>. Accessed April 13, 2021.
- Clozapine orally disintegrating tablet [package insert]. Morgantown, WV: Mylan Pharmaceuticals; April 2021.
- Clozaril [package insert]. Rosemont, PA: HLS Therapeutics; February 2021.
- Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. 2020;77(4):349-358. doi: 10.1001/jamapsychiatry.2019.4379.
- Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. *Am J Psychiatry*. 2015;172(9):870-880.
- Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. *Depress Anxiety*. 2006;23:364-372.
- Crismon M, Smith T, Buckley PF. Schizophrenia. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V, eds. *Pharmacotherapy: A Pathophysiological Approach*, 11<sup>th</sup> ed. McGraw-Hill; Accessed April 8, 2021. <https://accesspharmacy-mhmedical-com.proxy.cc.uic.edu/content.aspx?bookid=2577&sectionid=224358695>
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. *Lancet*. 2014;383(9916):533-540.
- Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. *J Clin Psychopharmacol*. 2008;28:S20-28.
- DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. *Bipolar Disorders*. 2009;11:483-93.
- Detke HC, DelBello, MP, Landry J, et al. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2015;54(3):217-224.
- DelBello MP, Goldman R, Phillips D. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry*. 2017;56(12):1015-1025. doi:10.1016/j.jaac.2017.10.006.

- Drugs@FDA: FDA approved drug products. Food and Drug Administration website. 2021. <http://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed April 9, 2021.
- Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. *J Clin Psychiatry*. 2015[a]; 76(12):e1574-1582.
- Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *Schizophr Res*. 2016;176(2-3):264-271.
- Durgam S, Greenberg WM, Li D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. *Psychopharmacology*. 2017;234(2):199-209.
- Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. *Schizophr Res*. 2014;152(2-3):450-457.
- Durgam S, Starace A, Migliore R, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. *Bipolar Disord*. 2015[b];17(1):63-75.
- Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. *Bipolar Disord*. 2020;22(4):372-384. doi: 10.1111/bdi.12852.
- Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: A systematic review and network meta-analysis. *J Child Adolesc Psychopharmacol*. 2019. doi:10.1089/cap.2018.0115.
- Fanapt [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; February 2017.
- FDA and Center for Drug Evaluation and Research (CDER). Summary Review: Vraylar (cariprazine). Food and Drug Administration website. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/204370Orig1Orig2s000SumR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000SumR.pdf). September 18, 2018. Accessed April 13, 2021.
- FDA Drug Safety and Availability: FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson's disease psychosis. Food and Drug Administration website. [https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm?utm\\_campaign=FDA%20analysis%20finds%20no%20new%20or%20unexpected%20safety%20risks%20associated%20with%20Nuplazid&utm\\_medium=email&utm\\_source=Eloqua](https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm?utm_campaign=FDA%20analysis%20finds%20no%20new%20or%20unexpected%20safety%20risks%20associated%20with%20Nuplazid&utm_medium=email&utm_source=Eloqua). September 20, 2018. Accessed April 13, 2021.
- FDA Drug Safety Communication: FDA modifies monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines. Food and Drug Administration website. <http://www.fda.gov/drugs/drugsafety/ucm461853.htm>. January 15, 2016. Accessed April 13, 2021.
- Food and Drug Administration (FDA). Caplyta (lumateperone) multidisciplinary review. December 20, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf). Accessed April 13, 2021.
- Food and Drug Administration (FDA). Secuado multi-discipline review. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/212268Orig1s000MultidisciplineR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212268Orig1s000MultidisciplineR.pdf). January 24, 2020. Accessed April 13, 2021.
- Findling RL, Drury SS, Jensen PS, et al; for the American Academy of Children and Adolescent Psychiatry (AACAP). Practice parameter for the use of atypical antipsychotic medications in children and adolescents. Approved by the AACAP Council on August 2, 2011. [https://www.aacap.org/App\\_Themes/AACAP/docs/practice\\_parameters/Atypical\\_Antipsychotic\\_Medications\\_Web.pdf](https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf). Accessed April 9, 2021.
- Findling RL, Landbloom RL, Szegedi A, et al. Aripiprazole for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. *J Am Acad Child Adolesc Psychiatry*. 2015;54(12):1032-1041.
- Findling RL, Pathak S, Earley W, et al. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol*. 2014;24(6):325-335.
- Fischer BA, Buchanan RW. Schizophrenia in adults: clinical manifestations, course, assessment, and diagnosis. UpToDate Web site. Updated December 8, 2020[a]. [www.uptodate.com](http://www.uptodate.com). Accessed April 8, 2021.
- Fischer BA, Buchanan RW. Schizophrenia in adults: epidemiology and pathogenesis. UpToDate Web site. Updated November 10, 2020[b]. [www.uptodate.com](http://www.uptodate.com). Accessed April 8, 2021.
- Fleischacker WW, Hobart M, Ouyang J, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. *Int J Neuropsychopharmacol*. 2016.pii:pyw076.
- Fornaro M, Stubbs B, De Barardis D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. *Int J Mol Sci*. 2016;17(2):241.
- Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: A meta-analysis of randomized-controlled trials. *Int Clin Psychopharmacol*. 2013;28(2):57-66.
- Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. *J Child Adolesc Psychopharmacol*. 2004 Spring;14(1):39-47.
- Gencer O, Emiroglu FNI, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder: an open-label maintenance study. *Eur Child Adolesc Psychiatry*. 2008;217-225.
- Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. *Pharmacotherapy*. 2013;33(10):1087-1106.
- Geodon [package insert]. New York, NY: Pfizer Pharmaceuticals; October 2020.
- Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. *Child Psychiatry Hum Dev*. 2014;45(2):185-192.
- Glick ID, Correll CU, Altamura AC, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data driven, personalized clinical approach. *J Clin Psychiatry*. 2011;72(12):1616-1627.
- Goldman R, Loebel A, Cucchiari J, Deng L, Findling RL. Efficacy and safety of lurasidone in adolescents with schizophrenia: A 6-Week, randomized placebo-controlled study. *J Child Adolesc Psychopharmacol*. 2017;27(6):516-525. doi:10.1089/cap.2016.0189.
- Grunz H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long term treatment of mixed states in bipolar disorder. *The World Journal of Biological Psychiatry*. 2017;19(1):2-58.
- Gulisano M, Cali PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. *Neurolo Sci*. 2011;32(6):1213-1217.

- Harvey PD, Ogasa M, Cucchiari, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. *Schizophrenia Research*. 2011;127:188-194.
- Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). *Cochrane Database Syst Rev*. 2016;(6):CD009043.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet*. 2019;394(10202):939-951.
- Hyman SL, Levy SE, Myers SM. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics*. 2020;145(1):e20193447. doi: <https://doi.org/10.1542/peds.2019-3447>.
- Iketani R, Furushima D, Imai S, Yamada H. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis. *Parkinsonism Relat Disord*. 2020;78:82-90. doi:10.1016/j.parkreldis.2020.07.021
- Invega [package insert]. Titusville, NJ: Janssen Pharmaceuticals; February 2021.
- Invega Sustenna [package insert]. Titusville, NJ: Janssen Pharmaceuticals; February 2021.
- Invega Trinza [package insert]. Titusville, NJ: Janssen Pharmaceuticals; February 2021.
- Jibson MD. Second-generation antipsychotic medications: Pharmacology, administration, and side effects. UpToDate website. [www.uptodate.com](http://www.uptodate.com). Updated February 23, 2021. Accessed April 8, 2021.
- Jones MP, Nicholl D, Trakas K, et al. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. *Int J Clin Pharmacol Ther*. 2010;48(6):383-399.
- Kamijima K, Higuchi T, Ishigooka J, et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). *J Affect Disord*. 2013;151(3):899-905.
- Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. *J Clin Psychopharmacol*. 2010[a];30:106-115.
- Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone from three clinical trials for the treatment of schizophrenia. *J Clin Psychopharmacol*. 2008;28:S29-S35.
- Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. *J Clin Psychiatry*. 2011;72(3):349-355.
- Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. *Schizophr Res*. 2015[a];164(1-3):127-135.
- Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. *J Clin Psychopharmacol*. 2015[b]; 35(4):367-373.
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd edition. *Am J Psychiatry*. 2020 Sep;177(9):868-872. Available at: <https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841>. Accessed April 8, 2021.
- Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2014;1:CD006569.
- Kishimoto T, Robenzadeh A, Leucht S, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. *Schizophr Bull*. 2014;40(1):192-213.
- Klemp M, Tvette IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of four atypical neuroleptic drugs compared to haloperidol and placebo. *J Clin Psychopharmacol*. 2011;31:698-704.
- Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2010 [a];(3):CD006654.
- Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2009[b]; (4):CD006627.
- Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2010 [b];(1):CD006625.
- Komossa K, Rummel-Kluge C, Schmid F, et al. Risperidone vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2011;(1):CD006626.
- Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2009[a];4:CD006569.
- Kumar A, Datta S, Wright S, et al. Atypical antipsychotics for psychosis in adolescents. *Cochrane Database Syst Rev*. 2013 Oct 15;10:CD009582.
- Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; December 2019.
- Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomized, double-blind, placebo-controlled trial. *Lancet*. 2015;386:2404-2412.
- Leucht S, Cipraini A, Spinelli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013; 382: 951-962.
- Leucht S, Corves C, Arbter D, et al. Second-generation vs first-generation drugs for schizophrenia: a meta-analysis. *Lancet*. 2009[a];373:31-41.
- Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry*. 2009[b];166:152-163.
- Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. *Biol Psychiatry*. 2016;79(12):952-961.
- Lieberman JA, Stroup TS, McElvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353(12):1209-1223.
- Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. *J Affect Disord*. 2017 ;213:138-150.
- Loebel A, Cucchiari J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014[a];171(2):169-177.

- Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014[bj];171(2):160-168.
- Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. *J Child Adolesc Psychopharmacol*. 2006;16(5):575-587.
- Macfadden W, Alphas L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. *Bipolar Disorders*. 2009;11(8):827-839.
- Maneeton N, Maneeton B, Putthi Sri S, Suttajit S, Likhitsathian S, Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. *Neuropsychiatr Dis Treat*. 2018;14:3063-3072. doi: 10.2147/NDT.S174622.
- Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2008;28(2):156-165.
- Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry*. 2009;48(11):1110-1119.
- Market Exclusive (ME) staff. Vanda Pharmaceuticals, Inc (NASDAQ:VNDA) Files An 8-K Other Events. [press release]. December 20, 2016. <https://marketexclusive.com/vanda-pharmaceuticals-inc-nasdaqvnda-files-an-8-k-other-events-2/49544/>. Accessed April 13, 2021.
- McClellan J, Kowatch R, Findling RL, et al; for the American Academy of Children and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2007;46(1):107-125.
- McClellan J, Stock S; for the American Academy of Children and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry*. 2013;52(9):976-990.
- McCracken JT, McGough J, Shah J, et al. Risperidone in children with autism and serious behavioral problems (RUPP). *N Engl J Med*. 2002;347:314-321.
- McDonagh MS, Dana T, Selph S, et al. Treatments for schizophrenia in adults: A systematic review. comparative effectiveness review no. 198. 2017. AHRQ Publication No. 17(18)-EHC031-EF. Rockville, MD: Agency for Healthcare Research and Quality.
- McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. *Am J Psychiatry*. 2005;162:1142-1148.
- McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. *Epidemiol Rev*. 2008;30:67-76.
- McIntyre RS, Cohen M, Zhao J, et al. A three-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disorders*. 2009[a];11:673-686.
- McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. *Journal of Affective Disorders*. 2010[b];126:358-365.
- McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *Journal of Affective Disorders*. 2010[a];122:27-38.
- McIntyre RS, Cohen M, Zhao J, et al. Asenapine vs olanzapine in acute mania: a double-blind extension study. *Bipolar Disorders*. 2009[b];11:815-826.
- Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. *Am J Psychiatry*. 2011;168:957-967.
- Meltzer L, Risinger R, Nasrallah M, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *J Clin Psychiatry*. 2015;76(8):1085-1090.
- Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone vs haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. *Eur Child Adolesc Psychiatry*. 2008;17:1-8.
- Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular Psychiatry*. 2005;10:79-104.
- Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). *Neurology*. 2006;66(7):996-1002.
- Muralidharan K, Ali M, Silveira LE, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. *J Affect Disord*. 2013;150(2):408-414.
- Murphy TK, Lewin AB, Storch EA, et al; for the American Academy of Children and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2013;52(12):1341-1359.
- Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. *J Child Neurol*. 2006;21(6):450-455.
- Nakamura M, Ogasa MS, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2009;70(6):829-836.
- Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *J Clin Psychopharmacol*. 2016;36(2):130-140. doi: 10.1097/JCP.0000000000000479
- National Institute of Mental Health (NIMH). Schizophrenia. NIMH website. <https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml>. Updated May 2018. Accessed April 8, 2021.
- Nuplazid [package insert]. San Diego, CA: Acadia Pharmaceuticals, Inc.; November 2020.
- Nussbaum A and Stroup T. Paliperidone palmitate for schizophrenia. *Cochrane Database Syst Rev*. 2012;6:CD008296.
- Orange Book: Approved drug products with therapeutic equivalence evaluations. Food and Drug Administration website. <https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed April 13, 2021.
- Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. *World J Biol Psychiatry*. 2017:1-11.
- Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*. 2009;124:1533-1540.
- Pagsberg AK, Tarp S, Glinborg D, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: A systematic review and network meta-analysis. *J Am Acad Child Adolesc Psychiatry*. 2017;56(3):191-202.

- Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin-reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2005;66(10):1326-1330.
- Perlis RH, Baker RW, Zarate CA, et al. Olanzapine vs risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. *J Clin Psychiatry*. 2006[a];67:1747-1753.
- Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry*. 2006[b];76:509-516.
- Perseris [package insert]. North Chesterfield, VA: Indivior, Inc.; December 2019.
- Pillay J, Boylan K, Carrey N, et al. First- and second-generation antipsychotics in children and young adults: Systematic review update. Comparative Effectiveness Review No. 184. AHRQ Publication No. 17-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. <https://www.ncbi.nlm.nih.gov/books/NBK442352/>. doi: <https://doi.org/10.23970/AHRQEPCCER184>. Accessed April 12, 2021.
- Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. *J Clin Psychiatry*. 2007;68:1492-1500.
- Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase three studies. *J Clin Psychopharm*. 2008;28:S4-S11.
- Potkin SG, Ogasa M, Cucchiario J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. *Schizophrenia Research*. 2011;132:101-107.
- Pringsheim T, Okun MS, Muller-Vahl K et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. 2019;92(19) 896-906.
- Qaseem A, Barry MJ, Kansagara D, et al. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2016;164(5):350-9.
- Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. *Biol Psychiatry*. 2010;68(2):156-162.
- REMS@FDA. Food and Drug Administration website. 2021. <http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm>. Accessed April 13, 2021.
- Rexulti [package insert]. Rockville, MD: Otsuka Pharmaceuticals Co., Ltd; March 2020.
- Riedel M, Schennach-Wolff R, Dehning MS, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. *Hum Psychopharmacol Clin Exp*. 2010; 25:116-125.
- Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceuticals; February 2021.
- Risperdal Consta [package insert]. Titusville, NJ: Janssen Pharmaceuticals; February 2021.
- Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial. *J Affect Disord*. 2015;174:296-302.
- Saphris [package insert]. Irvine, CA: Allergan USA, Inc.; February 2017.
- Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. *Pharmacopsychiatry*. 2010; 43:e1-e10.
- Secuado [package insert]. Japan Saga Tosu: Hisamitsu Pharmaceutical Co., Inc.; October 2019.
- Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2020.
- Seroquel XR [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2020.
- Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. *Int Clin Psychopharm*. 2011;26:130.
- Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics*. 2004;114:e634-e641.
- Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/ fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. *J Clin Psychiatry*. 2005;66:1289-1297.
- Silva MT, Zimmermann IR, Galvao TF, et al. Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. *J Affect Disord*. 2013;146(3):310-318.
- Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. *PLoS Med*. 2013;10(3):e1001403. doi: 10.1371/journal.pmed.1001403.
- Steffens DC, Nelson JC, Eudicone JM, et al: Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. *Int J Geriatr Psychiatry*. 2011; 26(6):564-572.
- Stovall J. Bipolar disorder in adults: epidemiology and pathogenesis. UpToDate website. [www.uptodate.com/](http://www.uptodate.com/). Updated January 15, 2020. Accessed April 8, 2021.
- Stovall J. Bipolar mania and hypomania in adults: choosing pharmacotherapy. UpToDate website. [www.uptodate.com/](http://www.uptodate.com/). Updated April 11, 2021. Accessed April 16, 2021.
- Stroup TS, Lieberman JA, McEvoy JP, et al; for the CATIE Investigators. Results of phase three of the CATIE schizophrenia trial. *Schizophr Res*. 2009;107(1):1-12.
- Stroup TS, Lieberman JA, McEvoy JP, et al; for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry*. 2006;163(4):611-622.
- Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.
- Szegedi A, Durgam S, Mackle M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with acute manic or mixed episode associated with bipolar I disorder. *Am J Psychiatry*. 2018;175(1):71-79. doi: 10.1176/appi.ajp.2017.16040419.
- Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. *BMC Psychiatry*. 2011;11:101.
- Tandon R, Cucchiario J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. *J Psychopharmacol*. 2016;30(1):69-77.
- Tarr GP, Glue P, Herbison P. Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania-a systematic review and meta-analysis. *Journal of Affective Disorders*. 2011;134:14-19.

- Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. *Acta Psychiatr Scand*. 2014;130(6):452-469.
- Teter CJ, Kando JC, Wells BG. Major Depressive Disorder. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. *Pharmacotherapy: A Pathophysiologic Approach, 10e*. McGraw-Hill; Accessed April 08, 2021. <https://accesspharmacy-mhmedical-com.proxy.cc.uic.edu/content.aspx?bookid=1861&sectionid=146064868>.
- Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2007;68:224-236.
- Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry*. 2015[b];76(9):1232-1240.
- Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder. *J Clin Psychiatry*. 2015[a];76(9):1224-1231.
- Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry*. 2003;60(11):1079-1088.
- Van Os J, Kapur S. Schizophrenia. *Lancet*. 2009;374(9690):635-645.
- Versacloz [package insert]. Tampa, FL: TruPharma, LLC.; August 2020.
- Veterans Administration (VA) and Department of Defense (DoD) Clinical Practice Guideline for Management of Major Depressive Disorder. VA/DoD website. April 2016. <http://www.healthquality.va.gov/guidelines/MH/mdd/>. Accessed April 9, 2021.
- Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. *J Clin Psychopharmacol*. 2010;30:579-590.
- Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. *Eur Neuropsychopharmacol*. 2012;22(11):825-835.
- Volkmar F, Siegel M, Woodbury-Smith M, et al; for the American Academy of Children and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):237-257.
- Vraylar [package insert]. Irvine, CA: Allergan USA, Inc.; May 2019.
- Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. A pooled analysis of six-week acute-phase pivotal trials. *J Clin Psychopharmacol*. 2008;28:S12-S19.
- Weiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. *CNS Drugs*. 2016;30(8):735-747.
- Weissman L. Autism spectrum disorders in children and adolescents: overview of management. UpToDate website. [www.uptodate.com/](http://www.uptodate.com/). Updated December 19, 2019. Accessed April 8, 2021.
- Wen XJ, Wang LM, Liu ZL, et al. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. *Braz J Med Res*. 2014;47(7):605-616.
- Yasue I, Matsunaga S, Kishi T, et al. Serotonin 2A receptor inverse agonist as a treatment for Parkinson's disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. *J Alzheimers Dis*. 2016;50(3):733-740.
- Yatham LN, Fallu A, Binder CE. A six-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. *Acta Psychiatr Scand Suppl*. 2007;(434):50-56.
- Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disorders*. 2018;20:97-170.
- Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. *Neuropsychopharmacology*. 2011;36:375-389.
- Yoo HK. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. *J Clin Psychiatry*. 2013;74(8):e772-e780.
- Yoon S, Jeon SW, Ko YH, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis. *J Clin Psychopharmacol*. 2017;37(1):46-53.
- Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). *J Clin Psychiatry*. 2010;71(2):150-162.
- Zyprexa Relprevv [package insert]. Indianapolis, IN: Eli Lilly and Company; July 2020.
- Zyprexa Zydys [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2020.
- Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2020.

Publication Date: April 30, 2021